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ABSTRACT OF DISSERTATION

INJURY ESTABLISHES CONSTITUTIVE µ-OPIOID RECEPTOR ACTIVITY LEADING
TO LASTING ENDOGENOUS ANALGESIA AND DEPENDENCE
Injury causes increased pain sensation in humans and animals but the mechanisms
underlying the emergence of persistent pathological pain states, which arise in the
absence of on-going physical damage, are unclear. Therefore, elucidating the
physiological regulation of such intractable pain is of exceptional biomedical importance.
It is well known that endogenous activation of µ-opioid receptors (MORs) provides relief
from acute pain but the consequences of prolonged endogenous opioidergic signaling
have not been considered. Here we test the hypothesis that the intrinsic mechanisms of
MOR signaling promote pathological sensitization of pain circuits in the spinal cord. We
found that tissue inflammation produces agonist-independent MOR signaling in the
dorsal horn of the spinal cord, which tonically represses hyperalgesia for months, even
after complete recovery from injury and re-established normal pain thresholds.
Disruption of this constitutive activity with MOR inverse agonists reinstated pain and
precipitated cellular, somatic and aversive signs of physical withdrawal. This
phenomenon required N-methyl-D-aspartate receptor activation of calcium-sensitive
adenylyl cyclase type 1. Thus, we present a novel mechanism of long-lasting opioid
analgesia that regulates the transition from acute to chronic pain while, in parallel,
generates physical dependence. In conclusion we propose that the prevalence of
chronic pain syndromes may result from a failure in constitutive signaling of spinal MORs
and a loss of endogenous analgesic control.
KEYWORDS: pain, NMDA receptor, adenylyl cyclase, allostasis, inflammation
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CHAPTER 1

Introduction and Background

1.1 Introduction and Overall hypothesis
Maladaptive plasticity within the central nervous system (CNS) contributes to
persistent pain states (Latremoliere and Woolf, 2009). Cellular models of chronic pain
include facilitatory mechanisms such as long-term potentiation (LTP) of synaptic strength
in dorsal horn neurons (Ikeda et al., 2006; Ruscheweyh et al., 2011) and opposing
mechanisms driven by µ-opioid receptors (MORs) expressed on primary afferent
terminals and spinal dorsal horn neurons that reduce neurotransmission (Heinke et al.,
2011). Exogenous administrations of opiates such as morphine provide powerful pain
relief in part by action in the superficial dorsal horn. Similarly, endogenous MOR
signaling, driven by endorphin and enkephalin peptide release is recruited following
tissue or nerve injury to reduce acute pain (Basbaum and Fields, 1984; Ossipov et al.,
2010).

MOR-mediated

dissociation

of

inhibitory

Gαi/o-βγ

complexes

reduces

neurotransmitter release (Heinke et al., 2011) and neuronal excitability (Yoshimura and
North, 1983) by several mechanisms, including modulation of inward-rectifying
potassium channels (KIR) and voltage-dependent calcium channels (VDCC), as well as
inhibition of adenylyl cyclase-mediated (AC) production of adenosine 3′,5′-cyclic
monophosphate (cAMP).
Chronic administration of exogenous opiates leads to the development of
compensatory neuroadaptations underlying opiate tolerance and dependence (Christie,
2008), including the selective upregulation of the calcium-sensitive AC isoforms, type 1
1

and type 8 (AC1 and AC8) (Avidor-Reiss et al., 1997; Lane-Ladd et al., 1997). Thus,
cessation of opiates leads to cellular and behavioral symptoms of withdrawal including
cAMP generation, synaptic plasticity, aversion and induces NMDA-Receptor (NMDA-R)dependent LTP at C fiber synapses in the spinal cord to precipitate hyperalgesia (Nestler
and Aghajanian, 1997; Angst and Clark, 2006; Kauer and Malenka, 2007; Drdla et al.,
2009; Heinl et al., 2011). An intriguing hypothesis of drug addiction suggests that chronic
opiates increase MOR constitutive activity (MORCA) to preserve physical and
psychological dependence (Wang et al., 1994; Liu and Prather, 2001; Wang et al., 2004;
Shoblock and Maidment, 2006; Meye et al., 2012), which is further enhanced by
enkephalin peptide release (Shoblock and Maidment, 2007). Whether MORs adopt
constitutive signaling states in other disease syndromes, such as chronic pain, remains
untested. Indeed, it is unknown whether endogenous opioidergic mechanisms can
induce physical dependence. Furthermore, while exogenously applied opioids prevent
(Terman et al., 2001; Benrath et al., 2004) and/or erase (Drdla-Schutting et al., 2012)
spinal LTP, the ability of the endogenous opioid system to persistently repress
pathological pain is unclear.
This dissertation tests the hypothesis that injury increases the proportion of
MORCA in the spinal cord to halt the transition from acute to chronic pain. We further
reasoned that, with time after injury, tonic MORCA would produce an endogenous cellular
and physical dependence in the CNS, thereby creating an increased susceptibility to
develop chronic pain.
1.2 General background
1.2.1. Pain: physiologic utility and chronic pathology
"Particles of heat" (A) activate a spot of skin (B) attached by a fine thread (cc) to a valve
in the brain (de) where this activity opens the valve, allowing the animal spirits to flow
2

from a cavity (F) into the muscles that then flinch from the stimulus, turn the head and
eyes toward the affected body part, and move the hand and turn the body protectively.”
- Descartes, Treatise of Man (1664)
René Descartes wrote that pain was transmitted directly from the periphery to the
brain by a single, direct, dedicated pain pathway (Figure 1.1). His dualistic Cartesian
mind-and-body model maintained the physical body as a mechanical system governed
by a soul (mind). Today we recognize this tract as the nociceptive pathway, part of the
larger somatosensory system, which integrates with higher-order brain circuits to create
the experience of pain. In this modern materialist view, physical states influence mental
states and vice versa. However, the transmission of nociceptive signals undergoes
extensive modulation at various anatomical locations throughout the nervous system
prior to cortical processing and conscious perception.

3

Figure 1.1. Illustration of “pain pathways” by Rene Descartes from Treatise of
Man.

4

The dorsal horn of the spinal cord is a key site for modulation of noxious
information. Thus, the relationship between detection of noxious stimuli at the periphery
and pain perception in the brain is far from linear, but integrative and modulatory.
According to the International Association for the Study of Pain (IASP), nociception is the
“neural processes of encoding and processing noxious stimuli”; whereas pain is defined
as “an unpleasant sensory and emotional experience associated with actual or potential
tissue damage, or described in terms of such damage”. This definition expounds that
pain involves both physical and psychological components. These sensory and affective
qualities are mediated by the somatosensory and limbic systems, respectively. The
sensory-reflexive component in humans and animals can be assessed utilizing reflexive
tests (e.g. von Frey filaments, Hargreaves’s thermal assay, etc.). The response to an
injury is determined by measuring the hypersensitivity of the limb to withdrawal from the
sensory stimuli. While the aversive-spontaneous component is determined by patient
self-reporting or motivation to seek pain relief in animals (i.e. Conditioned Place
Preference for analgesics). Both aspects of pain (sensory and emotional) need further
consideration, from the basic and clinical sciences, to develop effective therapeutics.
Acute or nociceptive pain is an evolutionarily conserved defense mechanism
which protects an organism from exacerbating injuries by potentially harmful and
damaging stimuli. Nociceptors, specialized sensory neurons, detect such threatening
stimuli and project to the central nervous system so that an appropriate behavioral
response can be made (e.g. withdrawal of a limb from a hot surface). Without such a
protective mechanism, rampant injuries would reduce survival and quality of life. This is
exemplified in rare human cases by individuals with genetic defects in nociceptor
receptors/channels that preclude the detection of nociceptive signals, leading to
extensive bodily damage, infection and shortened lifespan (Indo et al., 1996;Cox et al.,
2006). Alternatively, pain may be associated with a specific underlying disease or injury
5

and can be a sign of illness that provokes appropriate measures such as rest or
medication to be taken. Thus, pain is typically considered a “symptom of something”.
It is when the hypersensitivity of the nociceptive system does not remit with the
healing or recovery of injury or illness that pain no longer serves a physiologic purpose,
becoming a primary clinical problem itself. The IASP defines pain persisting for periods
longer than four months as chronic pain. Here, chronic pain results from a dysfunction
of the somatosensory system or limbic circuits that feed into the somatosensory system,
brought about by inflammation or neuropathy for example, and are regarded as a
pathological disease state.
Comorbidities such as depression, anxiety and sleep disorders are common.
Chronic pain also reduces the ability of patients to socialize and maintain relationships
and can have a significant negative impact on employment, exacerbating economic
burden on businesses and state-run healthcare programs. The needs of chronic pain
patients to date are largely unmet with a lack of good therapeutic drugs as well as a lack
of recognition by physicians that their pain is more than a “symptom of something.”
Thus, a greater appreciation for chronic pain as a pathological disease entity, improved
diagnostic procedures and the development of novel pharmacological treatments are
desperately required to combat the clinical problem of chronic pain.
While novel therapeutics are not directly investigated in this dissertation, a major
goal of this research is to present several new targets for future therapies. Development
of novel treatments will be aided by a greater understanding of the pathological
mechanisms which convert acute pain to chronic pain and the endogenous counteradaptations that attempt to restore normal signaling within the nociceptive circuitry.
1.2.2. Anatomy of nociceptive circuitry: systems and cellular level
1.2.2.1 Peripheral sensory afferents
6

The sensory experience begins in the peripheral nervous system, where the
distal terminals of primary afferent fibers respond to a myriad of stimuli and translate this
information through electrical signals into the dorsal horn of the spinal cord, where the
central ends of these fibers terminate. There are three main types of sensory neuron
fibers in the peripheral nervous system, Aβ-fibers, Aδ-fibers and C-fibers, each
possessing different properties allowing them to respond to and transmit different types
of sensory information. Aβ-fibers are large in diameter and highly myelinated, allowing
rapid action potential conduction (30-80 m/s). These fibers have low activation
thresholds and normally respond to light touch and joint movement and are responsible
for conveying tactile information. Aδ-fibers are smaller in diameter and thinly myelinated;
possess higher activation thresholds with a slower conduction velocity of 6-30 m/s. They
respond to both thermal and mechanical stimuli. C-fibers have the smallest axonal
diameter and are unmyelinated, thus making them the slowest conducting, at 0.5-2 m/s.
They have the highest thresholds for activation and therefore detect selectively
nociceptive or “painful” stimuli. There are two main classes of C-fibers, peptidergic and
non-peptidergic. Collectively both Aδ-fibers and C-fibers can be termed as nociceptors
or “pain fibers”, responding to noxious mechanical, thermal or chemical stimuli. It is
assumed that Aδ-fiber nociceptors mediate “fast” pain which can be described as welllocalized, acute, sharp pain, while C-fiber nociceptors mediate “secondary pain” which is
delayed, more diffuse and dull (Basbaum et al., 2009).

1.2.2.2 Central innervation and signal transduction
The central terminals of primary afferent fibers enter the spinal cord via the
dorsal root entry zones and terminate in specific regions of the dorsal horn, synapsing
with second order dorsal horn sensory neurons. For the sciatic nerve, there are three
distinct branches (tibial, common peroneal and sural nerves) which retain somatotopic
7

organization in the central innervation zones (Corder et al., 2010). All sensory fibers
release glutamate, the predominant excitatory neurotransmitter in the central nervous
system (CNS), to facilitate excitatory nociceptive transmissions. Peptidergic C-fibers as
well as some Aδ-fibers release calcitonin gene related peptide (CGRP). In addition,
peptidergic C-fibers may also release substance P, brain-derived neurotropic factor
(BDNF), somatostatin and galanin (Ju et al., 1987). Action potentials arriving at the
central terminal activate the vesicle-release machinery to induce neurotransmitter
release, a process dependent on Ca2+ influx into the afferent terminal mediated by N-,
P/Q- and T-type voltage-gated Ca2+ channels. Interestingly, the central terminals of
primary afferent fibers closely resemble their peripheral terminals in that they express
similar receptors and channels (e.g. TRPV1, TRPA1, P2X3 and BK2 receptors, etc.)
(Snider and McMahon, 1998; Woolf and Ma, 2007). It is believed that activation of these
pre-synaptic receptors in the dorsal horn acts to increase excitatory neurotransmitter
release. In contrast, inhibitory signaling mediated by opioid receptors, γ-amino butyric
acid (GABA) receptors, Neuropeptide tyrosine (NPY) receptors and cannabinoid (CB)
receptors act to counter neurotransmitter release (discussed in greater detail below).
1.2.2.3 Anatomical arrangement of the dorsal horn of the spinal cord
Within the grey matter of the spinal cord, intrinsic spinal neurons can be
anatomically organized into diverse laminae based on innervation and projections. In the
early 1950s, Rexed first divided the spinal cord grey matter of the cat into a series of
parallel laminae, numbered I to X, providing a uniform description of the arrangement of
the spinal cord regardless of the particular spinal segment under investigation (Rexed,
1954). This scheme has since been applied to other species, including rodents.
Together, laminae I and II are often described as the superficial dorsal horn or the
substantia gelatinosa, and this is the main synaptic region for terminating nociceptive
primary afferents. The remainder of the dorsal horn comprises four further laminae (III8

VI), with laminae V-VI often collectively referred to as the deep dorsal horn. Laminae VIIIX form the ventral horn of the spinal cord, while lamina X, surrounds the central canal.
1.2.2.4 Anatomy of ascending projections from the dorsal horn to the brain
The output from the dorsal horn to higher centers in the brain is carried by spinal
projection neurons along ascending pathways. A large population of projection neurons
are found superficially in lamina I. The majority of these neurons have axons which cross
the midline and ascend in the contralateral white matter (Todd, 2002). It is estimated that
80% of these cells express the neurokinin 1 (NK1) receptor for substance P (Todd,
2002; Mantyh et al., 1997; Mantyh and Hunt, 2004). NK1+ cells in lamina I project to
brain structures such as the thalamus, the periaqueductal grey (PAG) and brainstem
structures such as the caudal ventrolateral medulla (CVLM) and the parabrachial
nucleus (PBN). Projections to the thalamus are relayed to cortical regions of the brain,
including the primary somatosensory cortex (S1), whereas the projections to the PBN
subsequently reach limbic structures such as the amygdala and hypothalamus, thus
contributing to the affective component of pain (Todd, 2002). From the PBN, signals are
also transmitted to other brainstem areas such as the PAG and the rostroventromedial
medulla (RVM), a region which has descending projections back to the dorsal horn.
Therefore, lamina I NK1-expressing cells can modulate spinal processing by activation
of descending pathways from the brainstem, thus forming a spino-bulbo-spinal loop.
These descending pathways can be influenced by limbic regions in the brain and so can
be altered by mood and attention.
Projection neurons contained in the deeper lamina of the dorsal horn, scattered
throughout lamina III to VI, project predominantly to the thalamus, thereby making up a
significant proportion of the spinothalamic tract. This ascending pathway carries primarily
sensory information and so provides the sensory discriminative component of the pain
experience. Many of these deep projection neurons have dendrites extending towars the
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to the superficial dorsal horn, thus allowing them to make synaptic contacts with
terminating C-fibers and receive noxious inputs (Woolf and King, 1987; Todd, 2002).
1.2.2.5 Anatomy of descending projections from the brain to the dorsal horn
Descending pathways from supraspinal structures are able to influence
nociceptive transmission in the dorsal horn of the spinal cord. Such descending
influences may be either excitatory (descending facilitation) or inhibitory (descending
inhibition) in nature and may equally engage primary afferent terminals or intrinsic dorsal
horn cells, both interneurons and projection neurons. In this way, the brain influences the
final output from the dorsal horn to cortical regions of the brain where pain is perceived.
Several key supraspinal structures have been identified which can directly or indirectly
modulate the dorsal horn, including the PAG in the midbrain and brainstem nuclei such
as the PBN, RVM and locus coeruleus (LC). Such descending modulatory pathways
access the spinal cord via the dorsolateral and ventrolateral funiculi. In addition, many of
the structures implicated in descending modulation can exert both facilitatory and
inhibitory influences in the dorsal horn, dependent on the context of the situation. Early
studies demonstrated that electrical stimulation of the PAG could produce analgesia in
the dorsal horn (Reynolds, 1969; Basbaum and Fields, 1984). However, direct
projections from the PAG to the cord are few in number. Rather, the PAG projects to and
modulates the output of brainstem nuclei and in this indirect way alters nociceptive
processing in the dorsal horn. Similar connectivity exists from the PBN to the dorsal horn
and these projections predominantly suppress responses of superficial dorsal horn
neurons to both innocuous and noxious inputs (Millan, 2002). Numerous transmitters
may be released by PAG and PBN projection neurons including substance P,
cholecystokinin (CCK), GABA and endogenous opioids (Millan, 2002). The RVM in the
brainstem receives the majority of its sensory inputs relayed through the PAG and PBN,
and in turn, sends axons directly to both superficial and deep dorsal horn laminae
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(Millan, 2002). Initial work suggested that the descending influence from the RVM is
inhibitory since electrical stimulation in this region produces analgesia via profound
inhibition of noxious inputs to superficial and deep dorsal horn neurons (Basbaum et al.,
1976; Fields et al., 1976; Fields et al., 1977). More recent work, however, has
demonstrated that descending facilitatory pathways also originate from the RVM,
particularly in chronic pain states (Burgess et al., 2002; Bee and Dickenson, 2007). This
bidirectional control of spinal processing is mediated by two distinct populations of RVM
cells. ON cells produce a burst of firing in response to peripheral noxious stimulation and
are inhibited by endogenous opioids, thus they are believed to trigger descending
facilitation. In contrast, OFF cells are inhibited by noxious inputs since they display a
transient disruption in their firing immediately prior to a nociceptive reflex and they are
disinhibited by endogenous opioids, thus they are implicated in descending inhibition
(Fields et al., 1983; Heinricher et al., 1992; Bannister et al., 2009).
As illustrated in Figure 1.2, the integration of nociceptive signals through the
peripheral, spinal, and supraspinal circuitries is required for the expression and
perception of pain.
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Figure 1.2. CNS pain pathways. Axon terminals of primary afferent nociceptors
transmit noxious signals to intrinsic projection neurons in the spinal cord dorsal horn.
The ascending nociceptive fibers relay the information to several supraspinal nuclei for
further processing.

Projections to the thalamus relay signals to the somatosensory

cortex providing information about location and intensity of the stimulus; projections to
the parabrachial nucleus relay signals to the amygdala and other limbic circuits for
valuation of pain affect; projections to the brainstem (e.g. periaquaductial gray and
rostral ventral medulla) engage descending feedback systems that modulate spinal cord
nociceptive processing. Adapted from Basbaum et al. Cell. 2009.
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1.2.3. Spinal cord nociceptive plasticity
The spinal cord is an important relay site at which various incoming sensory and
nociceptive signals undergo convergence and modulation. Spinal neurons are under
ongoing control by peripheral inputs, interneurons and descending controls. One
consequence of this modulation is that the relationship between stimulus and response
to pain is highly plastic. The response of projection neurons is greatly altered following a
peripheral afferent barrage, as produced by electrical stimulation, inflammation or nerve
damage, via the influence of various neurotransmitter systems in the spinal cord, which
are similarly subject to plasticity, particularly during pathological conditions. This
prolonged pre-synaptic input can lead to spinal nociceptive plasticity such as long-term
potentiation (LTP) and central sensitization of dorsal horn neurons. Central to the
induction of these events is stimulation of dorsal horn glutamatergic NMDA receptors
which can promote activation of intracellular signaling pathways that contribute to such
pronociceptive plasticity.
Under pathological sensitization, neuronal responses to afferent inputs increase,
as does receptive field size (also known as secondary pain), while spontaneous action
potential firing is induced or enhanced. Together, these mechanisms of plasticity
contribute to the establishment of chronic pain states which manifest clinically in patients
as a heightened response to painful stimuli (hyperalgesia) and pain resulting from
normally non-painful stimuli (allodynia), as well as spontaneous, ongoing pain in the
absence of an evoking stimulus.

1.2.3.1. Central sensitization of dorsal horn neurons
According to the IASP, central sensitization corresponds to an enhancement in
the functional status of neurons and circuits in nociceptive pathways throughout the
neuraxis caused by increases in membrane excitability, synaptic efficacy, or a reduced
13

inhibition (Latremoliere and Woolf, 2009). The net effect is that previously subthreshold
synaptic inputs generate an increased action potential output, a state of facilitation,
potentiation, or amplification.
The demonstration of central sensitization in dorsal horn neurons provided the
first evidence of a central component of nociceptive hypersensitivity in chronic pain
(Woolf, 1983). In this early study, the responses from α-motor neuron efferents were
recorded as a measure of the output of dorsal horn processing, while stimulating
afferents both at the hindpaw and directly via the sural nerve. Prior to peripheral injury,
the majority of efferents exhibited minimal spontaneous activity and responded
exclusively to noxious, high threshold mechanical and thermal stimulation at the
hindpaw. A thermal injury was then induced at the hindpaw (75°C for 60 s) which caused
mild inflammation and produced significant changes in efferent properties. Spontaneous
activity increased and mechanical thresholds to von Frey hairs were markedly reduced.
The amplitude and duration of responses evoked by both noxious pinch and electrical
stimulation of the sural nerve, at noxious intensities, were also increased. Interestingly,
electrical stimulation of Aβ-fibers began to elicit responses in efferents which had been
absent prior to peripheral injury indicating that dorsal horn neurons in the pathway had
reduced thresholds. Furthermore, the cutaneous receptive fields expanded greatly and
even extended to the contralateral hindpaw, providing definitive evidence that this
sensitization could not be solely mediated by peripheral sensitization. Subsequent
studies demonstrated that, in addition to peripheral thermal injury and electrical
simulation, central sensitization of dorsal horn neurons could also be induced by
peripheral injection of chemicals such as formalin (Dickenson and Sullivan, 1991), and
capsaicin (Drdla-Schutting et al., 2012). Furthermore, it was demonstrated that central
sensitization is an NMDA-dependent phenomenon and that activity of NMDA receptors
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is required for both the induction and maintenance of central sensitization (Latremoliere
and Woolf, 2009).
In this dissertation, we hypothesize that NMDA-R-dependent sensitization, within
central nociceptive circuits, may underscore the mechanisms driving the emergence of
pathological pain states. Thus, in Chapter 3, we will investigate the interactions of the
endogenous opioidergic systems, with the spinal NMDA-R pathways, as they pertain to
long-lived neural facilitation and sensitization (see Figure 3.4 for schematic diagram of
signaling pathways involved in opioidergic masking of latent central sensitization).
It is important to note that plastic changes induced by peripheral injuries have
been demonstrated in neurons at supraspinal sites, representative of the general
phenomenon of central sensitization (Lee et al., 2008; Latremoliere and Woolf, 2009). In
this dissertation, use of the term central sensitization is restricted to the spinal cord and
specifically to central sensitization of dorsal horn sensory neurons. A multitude of studies
have now demonstrated that central sensitization within the dorsal horn involves
numerous mechanisms which work in concert to increase the excitability of spinal
sensory neurons in chronic pain states. These mechanisms include signaling pathways
which increase the intrinsic excitability of dorsal horn neurons, diminished spinal
inhibition and increased facilitatory influences from supraspinal sites.
Downstream of NMDA receptor activation, various intracellular signaling
cascades are activated, often via Ca2+ influx through the NMDA receptor channel, which
promote the increased excitability of dorsal horn neurons, contributing to central
sensitization. Such intracellular effectors include the extracellular signal regulated kinase
(ERK), Ca2+/calmodulin-dependent kinase II (CaMKII), Ca2+-sensitive adenylyl cyclases,
PKA, PKC and the tyrosine kinase Src (Ji et al., 1999; Fang et al., 2002; Zou et al., 2002
Kawasaki et al., 2004; Kohno et al., 2008). These kinases can enhance activity of both
AMPA and NMDA receptors during early-onset central sensitization by phosphorylating
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key regulatory sites, as well as increasing receptor numbers by promoting membrane
trafficking and insertion, thus increasing synaptic strength (Fang et al., 2003; Brenner et
al., 2004). Late-onset central sensitization, like late-phase LTP, requires transcriptional
changes driven by transcription factors such as the cAMP response element binding
protein (CREB), which is phosphorylated during central sensitization (Ji and Rupp,
1997). This phosphorylation may be regulated by ERK and contributes to expression of
genes such as c-Fos, a marker of neuronal activation following noxious stimulation (Hunt
et al., 1987).
As we will propose in Chapter 3, that NMDA-R-dependent signaling is initiated
upon the abrupt loss of endogenous opioid receptor signaling, we will also investigate
the downstream cascades involved in persistent central sensitization. One hypothesis
we will test is that specific components (e.g. adenylyl cyclase type 1) of excitatory
cascades are upregulated or “primed” by injury. These primed pathways, when activated
via disinhibition from the loss of opioidergic-mediated negative regulation, may trigger de
novo LTP-like mechanisms to enhance synaptic strength in the spinal nociceptive
circuitry (Figure 3.4).
1.2.3.2. Spinal long-term potentiation
LTP, first demonstrated in the hippocampus, is a ubiquitous mechanism
throughout the central nervous system underlying a long-lasting localized increase in
synaptic strength (Bliss and Lomo, 1973). Hippocampal LTP is believed to be the
neuronal substrate of learning and memory (Bliss and Collingridge, 1993) and is
dependent on activation of NMDA receptors, since NMDA antagonism prevents LTP
without effect on normal synaptic transmission (Collingridge et al., 1983). Interestingly,
spinal LTP related phenomena have also been reported in several animal pain models
following both inflammation or nerve damage, and recent studies have demonstrated
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that LTP can be induced in spinal and brain nociceptive pathways (Ji et al., 2003;
Sandkuhler, 2007). As a result, it has become clear that similarities and probably
common intracellular signaling pathways between central sensitization in the spinal cord
and LTP in the hippocampus exist. The generation of spinal LTP may be one
mechanism whereby acute pain is converted to chronic pain.
LTP could be induced in the superficial dorsal horn by high and low frequency
tetanic electrical stimulation at C-fiber intensity (100 Hz) of dorsal roots using an in vitro
spinal cord slice preparation (Randic et al., 1993; Ikeda et al., 2006), as well as in vivo
by recording superficial C-fiber evoked field potentials (Liu and Sandkuhler, 1995).
Natural stimuli, such as noxious heat and pinch applied to the skin, formalin or capsaicin
injection into the hindpaw and acute physical injury to peripheral nerve also generate
spinal LTP (Sandkuhler and Liu, 1998). Thus, spinal LTP was suggested to be a
mechanism underlying afferent-induced hyperalgesia. This LTP in the superficial dorsal
horn induced by both electrical HFS and natural noxious stimuli was blocked by NMDA
antagonism.
Signal transduction pathways involved in spinal LTP are similar to those reported
for hippocampal LTP. Specifically, inhibitors of calcium/calmodulin-dependent protein
kinase II (CaMKII), PKA, PKC and PLC all have been shown to prevent induction of
spinal LTP. Activation (phosphorylation) of mitogen-activated protein kinases (MAPKs)
under different persistent pain conditions is involved in the induction and maintenance of
pain hypersensitivity (Xin et al., 2006). In particular, nociceptive activity induces
phosphorylation of spinal extracellular signal-regulated kinase (ERK) via multiple
neurotransmitter receptors. Activated ERK, using different second messenger pathways,
regulates the activity of glutamate receptors and potassium channels and induces gene
transcription (Ji et al., 2009), and is therefore positioned to participate in both LTP
induction and maintenance.
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Recently, it was discovered that LTP at C-fiber synapses in the superficial dorsal
horn of the spinal cord is induced during exogenous opioid withdrawal (Drdla et al.,
2009), suggesting that LTP contributes to the hyperalgesia associated with opioid
withdrawal (Angst and Clark, 2006). This novel form of LTP is induced postsynaptically,
sharing mechanisms with stimulation-induced LTP, as it is abolished by preventing
postsynaptic Ca2+ rise and by blocking postsynaptic G-protein coupled receptors or
postsynaptic NMDA receptors. Although not yet tested it is possible that opioidwithdrawal LTP would exacerbate preexisting hyperalgesia or spontaneous pain by
further strengthening nociceptive synaptic facilitation.
The research presented in this dissertation begins to investigate these open
questions, as potential mechanisms for the emergence of chronic pain. 1. Does loss of
tonic endogenous opioidergic signaling result in spinal NMDA-R-dependent LTP? 2. Is
endogenous opioid withdrawal-LTP a causative mechanism in the development of
chronic pain?

1.2.4. Loss of spinal inhibition contributes to mechanical hypersensitivity and allodynia
Low threshold inputs from Aβ-fibers contribute to an inhibitory control of lamina I
neurons, decreasing spinal output of nociceptive information. This is the basis of the
Gate Control Theory, which postulates that inhibitory interneurons within the spinal cord
dorsal horn “gate” the flow of nociceptive information that is transmitted up to the brain
(Melzack and Wall, 1965). Additionally, it has been suggested that low threshold inputs
may activate inhibitory interneurons in the dorsal horn which prevent Aβ-fiber
polysynaptic inputs reaching lamina I from deeper lamina (Torsney and MacDermott,
2006). Blockade of spinal inhibition, through the intrathecal administration of GABA
receptor (bicuculline) or glycine receptor (strychnine) antagonists, resulted in pain
evoked by light tactile stimulation, equivalent to mechanical allodynia observed in pain
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patients (Yaksh, 1989). Therefore it was suggested that loss of spinal GABAergic and
glycinergic inhibition might underlie the clinical manifestation of mechanical allodynia in
chronic pain states. In the absence of spinal inhibition, a multi-synaptic pathway
involving polysynaptic, NMDA-dependent input from Aβ-fibers in lamina III is disinhibited
and can now activate lamina I projection neurons, effectively converting them to wide
dynamic range (WDR) neurons (Torsney and MacDermott, 2006). In this way, low
threshold stimulation may be processed and transmitted to higher centers to be
interpreted as painful. Spinal administration of strychnine alone produces behavioral
mechanical

hypersensitivity

(Yaksh,

1989)

as

well

as

enhanced

neuronal

responsiveness to light mechanical stimuli (Sorkin and Puig, 1996). This neuronal
hypersensitivity is selectively blocked by NMDA antagonists (Sorkin and Puig, 1996).
Thus, it is likely that any reduction in spinal inhibition results from an increased
inhibitory or reduced excitatory control of inhibitory interneurons. Alternatively, Coull and
colleagues proposed that failure of GABAergic inhibitory control of low threshold inputs
in the superficial dorsal horn of neuropathic rats might arise from a loss of the Cltransporter protein KCC2 (Coull et al., 2003; Coull et al., 2005). This results in
accumulation of intracellular Cl- in lamina I cells which, when activated by GABA
released from inhibitory interneurons, are then depolarized rather than hyperpolarized
due to Cl- efflux, thus effectively making GABA excitatory. This mechanism would
contribute to the unmasking of a normally silent polysynaptic Aβ-fiber input to lamina I
cells, so that these cells can respond to innocuous mechanical stimulation, leading to
behavioral static mechanical hypersensitivity following nerve injury.
This logical line of thought, loss of endogenous inhibitory regulation, as a
mechanism for chronic pain is very intriguing, yet remains incomplete. The balance or
ratio between excitation and inhibition has recently been shown as a crucial factor in
determining abnormalities in cortical information processing and behavioral output
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(Yizhar et al., 2011). In similar fashion to GABAergic signaling, opioidergic signaling
provides inhibitory balance to curtail increased excitation. Thus, it stands to reason, that
loss of this endogenous opioid inhibition may also result in an imbalance in excitatory
transmission and promote the emergence of chronic pain. Chapter 6 will further discuss
and analyze the current results presented in this dissertation within the context of
excitation/inhibition balance.
1.2.5. Endogenous opioid system
The opioid receptors are widely distributed in the nervous system (Yaksh, 1987;
Mansour et al., 1988) and their activation either by endogenous ligands (e.g. endorphins,
enkephalins, dynorphins and endomorphins) or by exogenously administered agonists
elicits powerful antinociception (Yaksh, 1987; Yaksh et al., 1988). All opioid receptor
subtypes (μ, δ, and κ-, and the nociception/orphanin FQ peptide receptor) are members
of the heterotrimeric guanosine 5′-triphosphate–binding protein (G protein)–coupled
receptor (GPCR) superfamily, Class A rhodopsin subfamily.
In addition to expression in peripheral nerve endings and dorsal root ganglia,
opioid receptors are highly expressed on the central terminals of primary afferents and
second order spinal cord neurons. Opioids receptors are largely localized presynaptically
on afferent terminals (70%), so substantial pain signal attenuation occurs before
information reaches postsynaptic neurons in the dorsal horn. Agonists of the opioid
receptors are known to modulate synaptic transmission through both pre- and postsynaptic mechanisms in the CNS. μ- and δ-opioid receptor agonists inhibit glutamatergic
synaptic transmission presynaptically in the superficial spinal dorsal horn (Jeftinija, 1988;
Hori et al., 1992; Glaum et al., 1994). Agonists dissociate Gαi/o which then inhibits
adenylyl cyclase production of cAMP, thus decreasing the opening of voltage-gated Ca2+
channels (VGCC) (Dickenson et al., 1987; Sullivan et al., 1989; Kohno et al., 1999;
Kondo et al., 2005) (Figure 1.3) . The dissociated Gαβγ subunit causes the opening of G
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protein-coupled inwardly-rectifying potassium channels (GIRKs) to further hyperpolarize
the neuron (Figure 1.3). Nociceptive transduction may be further attenuated by opioid
activity on excitatory interneurons (Spike et all, 2002; Marker et al., 2006). The
dissertation research will primarily focus on investigating opioidergic inhibition/regulation
of spinal adenylyl cyclases, specifically the calcium-sensitive adenylyl cyclase type 1.
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Figure 1.3. Opioidergic signaling. Opioid ligands bind to the extracellular binding
pocket of opioid receptors producing activation of intracellular inhibitory G-proteins
(Gαi/o─βγ).

Dissociated

G-proteins

can

reduce

neuronal

excitation

and/or

neurotransmitter release via inhibition of adenylyl cyclases (AC), voltage-gated calcium
channels (VGCC), and activation of inward-rectifying potassium channels (GIRK). Red
blunted lines indicate inhibition and blue arrow lines indicate activation.
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Opioid signaling also occurs at numerous regions in the brain, including anterior
cingulate cortex, nucleus accumbens, ventral tegmental area, locus coeruleus,
amygdala, and prefrontal cortex to disrupt the perceptual modification of pain processing
(Tracey, 2007; Baliki et al., 2010). Additionally, top-down descending inhibition involves
actions of endogenous opioids on descending pathways that include the locus coeruleus
and the periaqueductal gray, leading to inhibition of spinal pain transmission (Fields,
2004; Schepers et al., 2008a; Heinricher et al., 2009; Zhang and Hammond, 2010). For
example, top-down activation from the periaqueductal gray induces endorphin and
enkephalin release onto 5HT (serotonin)-producing nucleus raphe magnus neurons in
the RVM. Raphe nuclei send axonal endings to the dorsal horn of the spinal cord to form
excitatory connections with GABAergic and enkephalinergic interneurons in the spinal
cord (Huang et al., 2008). Although not yet demonstrated, these interneurons, when
activated, could release enkephalin to bind the pre-synaptic opioid receptors on
incoming C and A-δ afferents from peripherally activated nociceptors to modulate the
signal.
Although a great majority of the following studies presented in this dissertation
focus on spinal mechanisms, supraspinal systems must be considered. Therefore, in
Chapter 3, we have provided preliminary studies investigating the contribution of
supraspinal opioidergic function in relation to persistent central sensitization.

1.3. Scope of thesis
Cutaneous noxious stimuli drive ascending pain transmission through the spinal
release of glutamate and peptide neurotransmitters from presynaptic terminals of
primary sensory neurons (Basbaum et al., 2009). Following repetitive or sustained
noxious input, enkephalins, endomorphins and dynorphins are released within the dorsal
horn (Yaksh and Elde, 1981; Basbaum and Fields, 1984; Iadarola et al., 1986; Noguchi
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et al., 1992; Song and Marvizon, 2003; Schepers et al., 2008b) and act at opioid
receptors to inhibit spinal excitatory transduction and persistent pain (Cesselin et al.,
1989; Zadina et al., 1997; Martin-Schild et al., 1998; Snyder, 2004; Trafton and
Basbaum, 2004). For example, in animal models, during the acute stages (within the first
14 days of the injury) of ongoing inflammatory pain, opioid receptor antagonists increase
mechanical and/or heat hypersensitivity (Millan et al., 1987; Herz and Millan, 1988;
Ossipov et al., 1996; Hurley and Hammond, 2000, 2001; Schepers et al., 2008b). Thus,
opioids orchestrate an adaptive compensatory response that modulates neuronal
excitability and fine-tunes glutamatergic nociceptive transmission via pre- (Hori et al.,
1992; Terman et al., 2001) and post-synaptic (Willcockson et al., 1984; Jeftinija, 1988;
Aicher et al., 2000) mechanisms in the spinal cord.
Endogenous opioid inhibition of acute nociception persists even after the initial
signs of hyperalgesia have subsided (Yu et al., 1994; Li et al., 2001; Guan et al., 2010;
Joseph et al., 2010; Campillo et al., 2011a). This is demonstrated by the ability of opioid
receptor antagonists to precipitate allodynia. These data led to the suggestion that tissue
injury induces a long-lasting, adaptive opioidergic inhibitory system that serves to
counterbalance latent nociceptive sensitization. My project extends these studies to
investigate long-lived opioidergic signaling mechanisms and the cellular consequences
on prolonged inhibition on the promotion of latent nociceptive sensitization.
The present studies were designed to investigate the molecular and
neurophysiological mechanisms driving the transition from acute to chronic pain, and the
mechanism by which this is inhibited by opioidergic activity. Specifically, we tested the
overall hypothesis that spinal MOR signaling, while beneficial in reducing injury-induced
hyperalgesia, becomes pathological, with time, in promoting the persistence of central
nociceptive sensitization via the allostatic regulation of Ca2+-sensitive adenylyl cyclase
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type 1. Thus, we will provide evidence that injured-induced tonic MOR signaling
simultaneously provides endogenous analgesia and, paradoxically, increases the
vulnerability to develop chronic pain.

Copyright © Gregory F. Corder 2013
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CHAPTER 2

The spinal endogenous opioidergic system opposes the transition from acute to
chronic pain

2.1 Introduction

Cutaneous noxious stimuli drive ascending pain transmission through the spinal
release of glutamate and peptide neurotransmitters from presynaptic terminals of
primary sensory neurons (Basbaum et al., 2009). Following repetitive or sustained
noxious input, enkephalins, endomorphins and dynorphins are released within the dorsal
horn (Yaksh and Elde, 1981; Basbaum and Fields, 1984; Iadarola et al., 1986; Noguchi
et al., 1992; Song and Marvizon, 2003; Schepers et al., 2008b) and act at opioid
receptors to inhibit spinal excitatory transduction and persistent pain (Cesselin et al.,
1989; Zadina et al., 1997; Martin-Schild et al., 1998; Snyder, 2004; Trafton and
Basbaum, 2004). For example, in animal models of ongoing or persistent inflammatory
pain, opioid receptor antagonists increase mechanical and/or heat hypersensitivity
(Millan et al., 1987; Herz and Millan, 1988; Ossipov et al., 1996; Hurley and Hammond,
2000, 2001; Schepers et al., 2008b). Thus, opioids orchestrate an adaptive
compensatory

response

that

modulates

neuronal

excitability

and

fine-tunes

glutamatergic nociceptive transmission via pre- (Hori et al., 1992; Terman et al., 2001)
and post-synaptic (Willcockson et al., 1984; Jeftinija, 1988; Aicher et al., 2000)
mechanisms in the spinal cord.
After traumatic injury, animals can develop long-lasting pain vulnerability: with
subsequent injury or stressor they become more susceptible to enhanced allodynia
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(Mishima et al., 1997; Aley et al., 2000; Rivat et al., 2002; Parada et al., 2003; Rivat et
al., 2007; Summer et al., 2007; Cabanero et al., 2009). This phenomenon is referred to
as latent nociceptive sensitization and may reflect a critical mechanism responsible for
the transition from acute to chronic pain (Rivat et al., 2007). Sensitization of pain
pathways can persist in the absence of behavioral signs of hypersensitivity (Reichling
and Levine, 2009; Asiedu et al., 2011b). Price and colleagues recently described a
model of latent nociceptive sensitization, where an injury that is associated with a
transient acute hypersensitivity produces a “priming” effect for enhanced allodynia that
persists in the spinal cord (Asiedu et al., 2011a).
The present studies were designed to investigate the molecular and
neurophysiological mechanisms driving the transition from acute to chronic pain, and the
mechanism by which this is inhibited by endogenous opioidergic activity. We will test the
hypothesis that injury-induced latent nociceptive sensitization is silenced by on-going,
tonic spinal MPR signaling.

2.2 Materials and Methods
2.2.1. Mice:

At the beginning of all experiments the subjects were naïve, adult (6-10

weeks), male C57Bl/6 (Charles River). All procedures were approved by the Institutional
Animal Care and Use Committee at the University of Kentucky in accordance with
American Veterinary Medical Association guidelines.
Mice were housed in plastic cages (bedding and enrichment) of 4 same-sex littermates
in a temperature controlled environment (14 hr: 10 hr light-dark cycle; lights on at 7:00
am) with ad libitum access to food and water. Upon arrival to the University of Kentucky
Division of Laboratory Animal Resources, mice were habituated to the colony housing
room for 1 week prior to any experimentation.
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Table 2.1. Animal use quantification for figures 2.1 – 2.7.

Figure

Group n at
start of
experiment

Group n
reported in
analysis and
figures

Comments on mouse
removal

Year of
experiment

2.1a

Sham: 10
CFA: 10
CFA+NTX: 8
CFA+saline: 8
Sham+NTX: 4
Sham+saline: 4
Saline: 6
NTX: 14
Sham: 6 per
dose
CFA: 6 per
dose
Saline: 7
NTX:7

Sham: 10
CFA: 10
CFA+NTX: 7
CFA+saline: 6
Sham+NTX: 4
Sham+saline: 4
Saline: 6
NTX: 13
Sham: 6 per dose
CFA: 6 per dose

n/a

2009

- Scratched through skin enough
for the pump flow modulator to
protrude out of body.
- infection
--

2011

n/a

2010

21d:
-saline: 7
-NTX:7
49d:
-saline: 5
-NTX: 6
77d
- saline: 5
- NTX: 5
105d
- saline: 5
- NTX: 5
Saline: 7
NTX: 11
CFA+CTOP:5
CFA+saline: 3
Sham+CTOP:3
Sham+saline: 3
Saline: 2
NTX: 2

- All loss of mice resulted from
death by littermate fighting over
the 105d observation period

2009

- All loss of mice resulted from
death by littermate fighting
- All loss of mice resulted from
death by littermate fighting

2011

- Additional loss of mice resulted
from death by littermate fighting
from the 105d timepoint group
listed in Figure 2.2b
st
nd
1 and 2 run were combined.
NMB group were issued more
mice to reduce the high variability
st
observed in 1 run.

2009

n/a

2009

n/a

2010

--

2010

2.1b

2.1c
2.1d

2.2a,b

2.2c
2.2d

2.2e

2.3a,b

Saline: 8
NTX: 12
CFA+CTOP:7
CFA+saline: 5
Sham+CTOP:6
Sham+saline: 6
Same mice
from Fig. 2.2a,b
st

1 run:
Saline: 5
NMB: 5
NTX: 5

Saline: 8
NMB: 10
NTX: 7

2009

2010

st

1 run: 2009
2

nd

run: 2012

nd

2.3c,d

2.3e

2.3f

2 run:
Saline: 3
NMB:5
NTX: 2
Saline: 5
NMB: 7
NTX: 7
--

CFA+NTX: 10
CFA+saline: 5
Sham+NTX: 8

Saline: 5
NMB: 7
NTX: 7
CFA+NTX: 8
CFA+saline: 7
Sham+NTX: 5
Sham+saline: 5
CFA+NTX: 10
CFA+saline: 5
Sham+NTX: 7
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Table 2.1 (continued)

2.4a

2.4b-d
2.4e

2.4f

2.5a-e

2.5f
2.6

2.7a-d

CFA+PTX: 6
CFA+vehicle: 4
Sham+PTX: 4
Sham: 10
CFA: 10
Sham+DAMGO
(10pmol): 8
Sham+DAMGO
(30pmol): 8
CFA+DAMGO
(10pmol): 8
CFA+DAMGO
(30pmol): 8
CFA+CTOP:7
CFA+saline: 6
Sham+CTOP:6
Sham+saline: 6

--

All groups: 6
CFA+NTX+touc
h stimulation: 4
CPxSx: 44

CFA+PTX: 6
CFA+vehicle: 4
Sham+PTX: 4
Sham: 9
CFA: 7
Sham+DAMGO
(10pmol): 8
Sham+DAMGO
(30pmol): 8
CFA+DAMGO
(10pmol): 8
CFA+DAMGO
(30pmol): 8
21d:
CFA+CTOP:7
CFA+saline: 5
Sham+CTOP:6
Sham+saline: 6
105d:
CFA+CTOP:5
CFA+saline: 3
Sham+CTOP:3
Sham+saline: 3
Sham: no light
touch: 5
Sham: light touch: 6
CFA: no light touch:
6
CFA: light touch: 6
CFA: light touch +
NTX: 7
All groups: 6
Representative
images from one
CFA+NTX mouse
i.t. saline: 11
s.c. saline: 11
s.c. NMB: 11
i.t. NTX: 11

n/a

2011

Spinal cords were damaged
during the dissection process
n/a

2012

- All loss of mice resulted from
death by littermate fighting

2010

- Same mice as in Figure 2.2d
for 105d pharmacology (graph is
duplicated)

n/a

2011

n/a
n/a

2011

n/a

2009

Unknown information is denoted by dashed lines (--).
Information that is not applicable is denoted as n/a
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2.2.2. Complete Freund’s Adjuvant (CFA) model of inflammatory pain:

As previously

described by Ren and Dubner (1999), immediately following baseline assessment of
mechanical thresholds, mice were lightly restrained and injected with CFA (5 µl of
1mg/1ml mycobacterium to oil emulsion, non-diluted; Sigma-Aldrich) into the intraplantar
surface (ventral-medial) of the left hindpaw. Sham injuries consisted of a saline injection
which controlled for needle puncture and subcutaneous injectate, (5µl, 0.9% NaCl). To
assess the development of tissue edema, we recorded the dorsal-ventral thickness of
the injured paw with a fine digital caliper (Mitutoyo, Illinois).
2.2.3. Spared Nerve Injury variant (CPxSx) model of neuropathic pain:

As previously

described by Shields et al (2003), peripheral nerve injury was induced by the ligation and
transection of the common peroneal (Cp) and sural (S) branches of the sciatic nerve
(CpxSx), leaving the tibial (T) branch intact. This is a variant of the spared nerve injury
(SNI) model (Decosterd et al., 2000; Bourquin et al., 2006). Anesthesia was induced with
5% isoflurane in oxygen and maintained with 2% isoflurane. The left hind-leg area was
shaved and wiped clean with alcohol. An incision was made in the skin of the mid-thigh.
The biceps femoris muscle was retracted, exposing the primary trifurcation of the sciatic
nerve. After ligation with 6.0 silk (Ethicon, Somerville, NJ), the knot and adjacent nerves
(2 mm) were transected. Care was taken to avoid contact with the T branch. The muscle
was sutured with absorbable 5-0 sutures and then the wound was closed with two 7 mm
sterile metal clips and wiped with Betadine. Sham operations were performed by
exposure of the sciatic nerve trifurcation, and then closure of the wound with care to
avoid nerve perturbation.
2.2.4. Mouse (in vivo) drug administration:

For

subcutaneous

injections

(200

µl),

unanaesthetized mice were lightly restrained and injected with a 27 G needle under the
skin of the back, above the lumbar region. For intrathecal injections (5 µl),
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unanaesthetized mice were lightly restrained and a 30 G needle attached to a Hamilton
microsyringe was inserted between the L5/L6 vertebrae, puncturing through the dura
(confirmation by presence of reflexive tail flick) as previously described (Fairbanks,
2003). For intraperitoneal injections unanaesthetized mice were lightly restrained and a
27 G needle was inserted through the abdominal wall into the peritoneal space and
drugs were administered in a 200 µl volume. For chronic drug infusions delivery, we
implanted subcutaneous osmotic mini-pumps (ALZET Osmotic Pumps, Durect
Corporation, Cupertino, CA, USA; model 2004, 0.25μl/hr for 14 d). Pumps were primed
in 37 °C saline for 48 hr prior to surgical implantation according to the manufacturer’s
instructions. Under isoflurane anesthesia (5% induction followed by 1.5-2.0%
maintenance), a subcutaneous pocket was created above the lumbar region of the
spinal column with a 1 cm skin incision above the scapulae, followed by blunt dissection
of the skin from the connective tissues with blunt tipped scissors. The pump was then
inserted with the flow moderator facing caudally, which rested just above the lumbar
region of the spinal column. The skin incision was then sutured closed and wiped with
Betadine. The pump was removed after 14d under anesthesia through the original
incision site, followed by sterile wound re-closure and wiped with Betadine.
2.2.5. Drug dosing:

The following drugs and doses were used for in vivo experiments:

naltrexone HCl (NTX, gift of the NIDA Drug Supply Program; subcutaneous: 0.003 –
10.0 mg / kg / body weight, dissolved in 200 µl saline; intrathecal: 1µg in 5µl saline),
naltrexone methobromide (NMB, gift of the NIDA Drug Supply Program; subcutaneous:
3 mg/kg in 200 µl saline; intrathecal: 0.3 µg in 5µl saline), naloxone (Sigma-Aldrich;
intraperitoneal: 3 mg/kg in 200 µl saline), Phe-Cys-Tyr-Trp-Orn-Thr-Pen-Thr-NH2
(CTOP, Sigma-Aldrich; intrathecal: 100 ng in 5µl saline), pertussis toxin (Sigma-Aldrich;
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intrathecal: 0.5 µg in 5µl water), [D-Ala2, N-Me-Phe4, Gly5-ol]-Enkephalin (DAMGO;
Sigma-Aldrich; intrathecal:10-30 pmol in 5 µl saline), and lidocaine (4%; 100 μl).
2.2.6. Mechanical hyperalgesia testing:

All testing was begun between 10:00 am -

noon in a temperature- and light-controlled room. Mice were acclimated for 30 - 60 min
in the testing environment within a custom rectangular plastic box (15x4x4 cm; 3 white
opaque walls and 1 clear wall) on a raised metal mesh platform. Baseline testing was
conducted prior to and after injury and drug injections at various time points shown in the
figure panels. To evaluate mechanical hypersensitivity (hyperalgesia), we used a
logarithmically increasing set of 8 von Frey filaments (Stoelting, Illinois), ranging in gram
force from 0.007 to 6.0 g. These were applied perpendicular to the ventral-medial
hindpaw surface with sufficient force to cause a slight bending of the filament. A positive
response was characterized as a rapid withdrawal of the paw away from the stimulus
fiber within 4 s. Using the modified up-down statistical method (Chaplan et al., 1994)
originally described by Dixon (1980), the 50% withdrawal mechanical threshold scores
were calculated for each mouse and then averaged across the experimental groups.
2.2.7. Heat hyperalgesia testing:

As previously described by Hargreaves et al.

(1988), mice were acclimated for 30 - 60 min in the testing environment within a circular
clear plastic tube (15cm H x 4cm D) on a glass table top (Ugo Basile). A radiant infrared
heat source (8V, 50W lamp, Ugo Basile) was directed to the ventral hindpaw
(Hargreaves et al., 1988). Beam intensity was adjusted to yield a baseline paw
withdrawal of 10-12 s. The heat source was calibrated throughout the study to maintain
this intensity. Three paw withdrawal time scores were recorded, with a cut off of 30 s,
and then averaged for analysis across the experimental groups.
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2.2.8. Cold allodynia testing: As previously described by Choi et al. (1994), to evaluate
hypersensitivity to a cool stimulus, a piece of PE-90 tubing, flared at the tip to a diameter
of 3 ½ mm, was used to apply a drop of acetone to the plantar paw. Surface tension
maintained the volume of the drop to 10 to 12 μl. Evaporation of the acetone cools the
skin to approximately 6°C. The time spent lifting the ipsilateral paw was recorded, with a
cut-off of 30 sec. This test was repeated 3 times and the results were averaged for
analysis.

2.2.9. Antinociception testing:As previously described by Eddy and Leimbach (1953), to
evaluate the antinociceptive effects of morphine mice were placed on a noxious 56 °C
hotplate. The time for the mice to flick, lift or lick their hindpaws was recorded during a
single trial, with a cutoff time of 30s to prevent tissue damage. Drug-induced effects on
the latency to respond were calculated as the Maximal Possible Effect for each
individual mouse:

Maximum Possible Effect (MPE); calculated as: MPE = [(drug

induced threshold – basal threshold) / basal threshold] X 100.

2.2.10. Phosphorylated Extracellular regulated kinase (pERK) stimulation studies:
2.2.10.1. Light-touch. A mechanical ‘Light-touch stimulation’ protocol was used
as previously described (Gao and Ji, 2010). Briefly, mice were injected with vehicle or
drug and then 30 min later anesthetized under isoflurane (5% induction and maintained
at 1.5%). A cotton-tip was gently stroked across the plantar surface of the ipsilateral
hindpaw, once every 5 s for 5 min. 5 min after the end of light-touch mice were
transcardially perfused with 10% buffered formalin and the lumbar spinal cord was
dissected. Control mice that did not receive the light-touch stimulation still underwent
isoflurane anesthesia 30 min after the intrathecal injection.
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2.2.10.2. Ambulation. The ‘Ambulation’ protocol consisted of an intrathecal
injection immediately followed by unrestrained walking on a metal mesh grate for 30 min.
Mice were then perfused and lumbar spinal cords dissected.

2.2.10.3.

Anesthesia. For

the ‘Anesthetized’ protocol, mice were first

anesthetized under isoflurane (1.5%) to prevent walking and joint movement, followed by
an intrathecal injection. Mice remained anesthetized for 30 min before they were
perfused and lumbar cords dissected.

2.2.10.4. Sciatic nerve block. For the “sciatic nerve block” protocol, mice were
first anesthetized under isoflurane (1.5%) followed immediately by an injection of 2%
lidocaine (100 µl) into the popliteal fossa in order to target the sciatic nerve that
innervates the hindpaw (protocol adapted from Okun et al. (2011), suing popliteal fossa
lidocaine injection in rats). Mice were then perfused and dissected 20 min later. This
dose and volume of lidocaine were chosen based on a pilot study in conscious, awake
mice which showed lack of reflexive responsiveness to noxious pin prick at the ipsilateral
hindpaw, lasting approximately 25-30 min. We also found that this dose of lidocaine
completely blocked the expression of spinal pERK following an intraplantar injection of
10% capsaicin.

2.2.11. Histology and Immunohistochemistry:

As described previously (Corder et

al., 2010), mice were deeply anesthetized with isoflurane or an intraperitoneal overdose
injection of Fatal Plus (86 mg/kg, Vortech Pharmaceuticals). Mice were then perfused
with ice-cold PBS/heparin followed by ice-cold 10% buffered formalin. Spinal cords (L3L5) were postfixed in 10% formalin, cryoprotected in 30% sucrose, and sectioned at 30
μm on a sliding microtome.
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Free-floating spinal cord sections were washed in 0.1M phosphate buffer, blocked in 3%
normal goat serum containing 0.3% Triton-X, and incubated overnight in primary
antibodies ((rabbit phospho-ERK1/2 antiserum (1:500, Cell Signaling), mouse NeuNAlexa488 (1:200, Millipore), rabbit MOR (1:500-2000; Neuromics)). Sections were
washed and incubated in Alexa 568-conjugated goat anti-rabbit antibody (1:700;
Invitrogen)) for 2 hr at room temperature, serial washed, slide mounted, and coverslipped with ProLong Gold + Dapi counterstain (Invitrogen).
For pERK quantification, 5 spinal sections, separated by at least 120 µm, were randomly
selected from each mouse. Images were taken on a Nikon TE2000 microscope (10x)
and the number of pERK+ profiles were counted by a blind observer (Jennifer Grasch
and Justin Pinson) and binned by Rexed lamina (I-II and III-V).
2.2.12. GTPγS35 binding assay:

As previously described by Winter and McCarson

(2005), the lumbar enlargement of the spinal cord was removed by hydrostatic pressure
ejection (18 G needle was used to push ~5 ml cold saline through the spinal column to
expel the spinal cord) and frozen on dry ice (performed by Greg Corder). Dr. Kenneth
McCarson and Michelle Winter (University of Kansas) were given the spinal cords for
further processing and analysis: 25 μm thick sections were cut and mounted on
positively charged glass slides. Sections were equilibrated in assay buffer (3 mM MgCl2,
100 mM NaCl, 0.2 mm EDTA, and 50mM Tris-HCl, pH 7.4) for 10 min and then in 1 mM
(β-FNA studies) or 2 mM (DAMGO studies) GDP for 15 min both at room temperature.
Agonist-stimulated binding was then performed with 1 mM or 2 mM GDP (β-FNA or
DAMGO, respectively) and 0.1 nM GTPγS35 (GE Healthcare, Little Chalfont,
Buckinghamshire, UK) and one of five serial dilutions ranging from 33 nM to 33 μM
DAMGO (Sigma-Aldrich) or 100 nM to 10 µM β-FNA (Sigma-Aldrich) in water treated
with a peptidase inhibitor cocktail containing 0.170 mg/ml bacitracin, 17 μg/ml leupeptin,
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17 μg/ml chymostatin, and 0.850 mg/ml bovine serum albumin. Drug was omitted and
replaced with either peptidase-treated water for basal determinations or 10 μM unlabeled
GTPγS in water for nonspecific binding determinations (nsb). Slides were incubated in
binding conditions at 24°C (room temp) for 2 hr and then rinsed twice with ice-cold 50
mM Tris-HCl, pH 7.4, for 2 min and twice with room temperature deionized water for 2
min. Slides were exposed to Kodak X-OMAT autoradiographic film (Sigma-Aldrich) for 8
h. Densitometry of images was performed by measuring the mean number of pixels in
lamina I of each left and right dorsal horn and subtracting the mean dorsal column
background value. Percent stimulation over basal was calculated using the following
equation:

Concentration-response curves were generated using non-linear regression curve-fitting,
and values for maximal stimulation (Emax) and half-maximal stimulating concentration
(EC50) were determined.
2.2.13. Statistics:

Data were analyzed using one-way or two-way ANOVA, as

indicated in the main text or figure captions, followed by Bonferroni post-hoc tests or
Student’s t tests as appropriate (GraphPad Prism v6). For dose-response hyperalgesia
studies the best-fit line was generated following non-linear regression analysis based on
each individual mouse’s Maximum Possible Effect (MPE); calculated as: MPE = (drug
induced threshold – basal threshold) / basal threshold; For GTPγS35 binding studies the
best fit line was generated following non-linear regression analysis. All data are
presented as mean ± the standard error of the mean (s.e.m.). Although standard
deviation (S.D.) provides direct indication of variance, while s.e.m. does not, and thus
S.D. is more appropriate, from a statistical standpoint presenting the s.e.m., is a
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commonly used practice in the behavioral pharmacology and pain fields (communication
from Drs. Bradley Taylor and Karin Westlund High).
2.2.14. Experimental blinding procedures: The experimenter, Greg Corder, was blind to
drug

treatments

during

all

behavioral

pharmacology

experiments.

This

was

accomplished by making each drug and vehicles in similar tubes and to the same
volume. These tubes were then given to Renee Donahue, Jennifer Grasch, Ryan
Griggs, Weisi Fu or Suzanne Doolen for tube coding. Greg was then given the tubes
marked with distinguishing letters. The code was typically kept hidden by the blinder until
completion of the experiment. After the experiment, the code was broken and Greg
analyzed the data.

2.3. Rationale and Results
2.3.1. Opioid receptor signaling provides acute pain relief and long-lasting intrinsic pain
suppression.
To model the progression of inflammatory pain following the unilateral hindpaw
intraplantar injection of complete Freund’s adjuvant (CFA), we assessed the
development of mechanical hypersensitivity in mice. Compared to saline injection, CFA
produced mechanical hypersensitivity (Figure 2.1a; F1,19 = 13.36, P < 0.001), evident as
a decrease in mechanical response threshold to von Frey filament stimulation of the
inflamed hindpaw. Mechanical hypersensitivity lasted 7d and fully resolved to a stable
baseline within 10d, demonstrating that the inflammatory pain naturally recovers.
Recently our lab found that conditional knockdown of neuropeptide tyrosine
(NPY) before the initiation of inflammation extended the time course of mechanical and
heat hyperalgesia (Solway et al., 2011). Similarly, dual blockade of cannabinoid CB1
and CB2 receptor signaling prevented the resolution of postoperative allodynia (Alkaitis
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et al., 2010). These studies suggest that endogenous NPY and endocannabinoids
hasten the resolution of acute pain. Thus pain intensity and duration are regulated by
numerous inhibitory systems, including spinally secreted opioid peptides and
subsequent activation of opioid receptors (Basbaum and Fields, 1984; Ossipov et al.,
2010). To determine whether endogenous opioid signaling promotes the intrinsic
recovery of acute inflammatory pain, we implanted subcutaneous minipumps to
chronically infuse naltrexone hydrochloride (NTX; 10 mg/kg/d), a non-selective opioid
receptor antagonist.

Compared to saline, NTX produced a robust, persistent

hypersensitivity throughout the 14d infusion period (Fig. 2.1b; F10,110 = 4.425, P < 0.0001,
2-way ANOVA, Drug x Time interaction), while having no effect in sham mice (P > 0.05
compared to Sham + saline). Upon NTX-minipump removal at 14d, mechanical
hypersensitivity gradually resolved, fully recovering in four days (P > 0.05, 18d compared
to baseline, Student’s t test). This suggests that peripheral tissue injury increases
adaptive opioidergic processes to relieve on-going pain. However, it is important to note
that chronic treatment with opioid antagonists (NTX and naloxone) can increase the
expression of μ, δ, and κ opioid receptors independent of nociceptive input (Yoburn et
al., 1995; Lesscher et al., 2003; Patel et al., 2003). However, our dose of NTX
(10mg/kg/d) appears sufficient to block all opioid signaling regardless of receptor
expression modulation that may have occurred (either from the antagonist or from the
CFA injury).
Hyperalgesic priming models, such as intraplantar IL-6 injection and the plantar
paw incision model of post-operative pain, suggest that the spinal nociceptive pathways
remain sensitized to subsequent injuries following recovery from the initial injury
(Reichling and Levine, 2009; Asiedu et al., 2011a). Opioid systems provide an
endogenous braking mechanism that exerts inhibitory control of acute pain intensity
soon after tissue injury (Ossipov et al., 2010), but whether MOR signaling is maintained
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for sufficient duration to oppose long-lasting nociceptive mechanisms is unknown.
Therefore to determine if nociceptive sensitization processes are masked by opioid
receptor signaling, we delivered NTX after the inflammatory pain had attenuated. When
administered 21d after CFA, systemic NTX reinstated mechanical hypersensitivity (Fig.
2.1c; F1,21 = 41.48, P < 0.0001). This effect peaked from 30 - 60 min and lasted
approximately 4 hr, a time course consistent with its reported plasma half-life in rodents
(Shader, 2003). The degree of NTX-induced pain reinstatement was dose-dependent,
with no observable effect in sham-injured mice (Figure. 2.1d).
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Figure 2.1. Peripheral inflammatory injury initiates endogenous opioid analgesia
to silence on-going nociceptive processes. (a) Time course for the development and
resolution of inflammatory mechanical pain induced by CFA (5 µl), as measured by von
Frey filaments (n = 10 mice per group). P < 0.05 compared to Sham group. (b)
Changes in mechanical pain resolution after continual minipump infusion of saline or
NTX (10 mg / kg /d) for 14d in Sham and CFA mice (n = 4 - 7 per group).  P < 0.05
compared to CFA + saline group,  P < 0.05 compared to Sham + NTX group. (c) Effect
of a single subcutaneous injection of saline (n = 6) or NTX (3 mg /kg)(n = 13) on
mechanical thresholds 21d after CFA.  P < 0.05 compared to Saline group. (d) Doseresponse effects of NTX on mechanical thresholds 30 min after subcutaneous injection
in Sham and CFA-21d mice (n = 6 per group per dose). Data shown as mean ± s.e.m.
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2.3.2. Tonic μ-opioid receptor signaling is present for months after injury.
Residual ipsilateral tissue inflammation persisted for 49d after CFA and was
absent by 77d (Figure 2.2a), therefore we examined if latent sensitization persisted
beyond, not just the recovery of pain, but recovery of the physical tissue injury.
Repeated injections of NTX but not saline reinstated mechanical hyperalgesia for at
least 105d post-CFA (Figure. 2.2b; 21d: F1,80 = 8.51, P = 0.0154; 49d: F1,72 = 58.79, P <
0.0001; 77d: F1,72 = 76.36, P < 0.0001; 105d: F1,64 = 33.15, P < 0.0001), and as late as
200d post-CFA (Figure 2.2e; n=2 per injection group, P = 0.025).
To control for possible context-dependent (associative) sensitization between the
testing environment and multiple drug injections (Adams and Holtzman, 1990; Taiwo et
al., 1989; Hummel et al., 2008), we injected CFA and left the animals undisturbed for
105 d. Again, we found that a single injection of NTX or the MOR-selective antagonist
CTOP, but not vehicle, elicited reinstatement of mechanical hypersensitivity (Figure. 2.2c
and d; NTX: F1,14 = 28.85, P < 0.0001; CTOP: F3,10 = 9.87, P = 0.0025). Taken together,
these results indicate that both excitatory and μ-opioidergic inhibitory processes remain
active for months, even in the absence of pain and tissue damage.
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Figure 2.2. Endogenous opioid analgesia and the opponent nociceptive processes
continue to operate for months beyond injury healing.
(a) Time course of paw edema after Sham and CFA injuries for 105d post injury
initiation. The effect of repeated subcutaneous saline or NTX administration on paw
edema is also noted. (b) Effect of repeated subcutaneous saline (n = 5 – 7 at each
injection) or NTX (3 mg /kg) injections on mechanical thresholds over 105d after CFA (n
= 5 – 7). These are the same mice shown in panel a. (c) Effect of a single subcutaneous
injection of either Saline or NTX (3 mg/kg) at 105d post CFA in mice naïve to drug
exposure and the behavioral testing environment (n = 7 – 11). (d) Effect of intrathecal
saline or CTOP on mechanical thresholds in sham and CFA mice 105d post injury
initiation (n = 3 - 5). (e) Effect of subcutaneous saline or NTX (3 mg/kg) at 200d post
CFA (n = 2 per group).  P < 0.05 compared to Saline group. Data shown as mean ±
s.e.m.
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2.3.3. Tonic opioid receptor signaling modulates latent nociceptive sensitization in the
spinal cord
Naltrexone hydrochloride (NTX) is lipophilic and therefore readily crosses the
blood-brain barrier (BBB), antagonizing opioid receptors at supraspinal, spinal, and
peripheral sites. To determine whether peripheral opioid receptor blockade can reinstate
pain hypersensitivity, we subcutaneously administered naltrexone methobromide (NMB),
an opioid receptor antagonist with a quaternary amine that restricts BBB permeability.
Unlike NTX, systemic NMB did not alter mechanical thresholds at the ipsilateral (Figure.
2.3a) or contralateral (Figure. 2.3b) paws when injected 21d after CFA.
Opioid receptors are highly expressed on the central terminals of primary
afferents and second order spinal cord neurons (Besse et al., 1990; Kohno et al., 1999;
Spike et al., 2002; Marker et al., 2005; Scherrer et al., 2009; Heinke et al., 2011). To
determine whether spinal opioid receptor blockade can reinstate pain hypersensitivity,
we administered receptor antagonists by direct lumbar intrathecal injection. We found
that either intrathecal NTX or NMB, but not saline, reinstated mechanical hypersensitivity
in both the ipsilateral (Figure. 2.3c, F2,63 = 25.40, P < 0.001) and contralateral paws
(Figure. 2.3d; P < 0.05), with no effect in sham-injured mice (Figure. 3.3e).
Opioid receptors are expressed on TRPV1 positive primary afferents in the spinal
cord (Chen and Pan, 2006). Therefore we also investigated if the reinstatement effect
of NTX is multimodal for heat hypersensitivity . As illustrated in Figure 2.3f,

CFA

decreased paw withdrawal latencies in response to noxious radiant heat (F1,15 = 14.94,
P < 0.0002). Heat withdrawal latencies returned to pre-injury values within 5 d after
injury. On day 21 post-CFA intrathecal NTX reinstated heat hypersenstivity (Figure. 2.3f;
F2,12 = 13.42, P < 0.0001), with no effect in sham controls (P > 0.05). Together these
data demonstrate that opioid receptors located in the spinal cord, and not the periphery,
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regulate mechanical and thermal nociception as blockade of spinal opioid tonic signaling
precipitates hyperalgesia.
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Figure 2.3. Blockade of spinal opioid analgesia reinstates mechanical and heat
hyperalgesia.
(a,b) Effect of subcutaneous injection of saline, NMB (3 mg/kg), and NTX (3 mg/kg) on
mechanical thresholds at the (a) ipsilateral and (b) contralateral paws. (n = 7-10)  P <
0.05 compared to Saline,  P < 0.05 compared to NMB. (c,d) Effect of intrathecal
injection of saline, NMB (300 ng), and NTX (1 µg) on mechanical thresholds at the (c)
ipsilateral and (d) contralateral paws. (n = 5-10).  P < 0.05 NTX compared to Saline, 
P < 0.05 NMB compared to Saline. (e) Effect of intrathecal NTX (1 µg) in sham injured
mice. (n = 5-8). (f) Effect of intrathecal saline or NTX (1 µg) on thermal heat thresholds
21d after CFA or sham injuries as measured by the Hargreaves’ radiant thermal heat
test. (n = 5-10). left:  P < 0.05 compared to Sham, right:  P < 0.05 compared to ‘CFA
+ saline’. Data shown as mean ± s.e.m.
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2.3.4. Increased spinal μ-opioid receptor::G-protein signaling
MOR-triggered intracellular second messenger signaling cascades are relayed
through coupled Gαi/o proteins. Therefore we next set to determine if MOR-G-protein
coupling and signaling is augmented following injury to suppress on-going nociceptive
processes:
First, we found that disruption of Gαi/o signaling with intrathecal injection of
pertussis toxin (an agent that causes ADP-ribosylation of Gi proteins, thus preventing
binding to GPCRs and loss of signal transduction), precipitated hyperalgesia in CFA-21d
but not shams (Figure. 2.4a; P < 0.05). This demonstrates the presence of injuryinduced tonic inhibitory G-protein signaling in the spinal cord.
Second, we (Greg Corder, Bradley Taylor, Michelle Winter and Kenneth
McCarson) assessed guanosine-5’-O-(3-[35S]thio)triphosphate

(GTPγS35) binding in

fresh spinal cord slices (Figure. 2.4b-d). GDP-bound G-proteins bind activated GPCRs
and are subsequently dissociated and activated by exchange of GDP from GTP. The
GTPγS35 analogue contains a sulfur residue, in lieu of a third O- molecule, on the γphosphate, which prevents hydrolysis to its di-phospho form.

Thus GTPγS35

incorporation into membrane preparations serves as a steady direct indicator of GPCRG-protein activity. We found that in control spinal cord slices derived from sham mice,
the MOR selective agonist DAMGO elicited a stimulation of GTPγS35 binding with an
Emax and EC50 of 58.02 ± 0.67% and 0.24 ± 0.01 µM, respectively (Figure. 2.4c). We
discovered that Emax was potentiated in 21 d CFA slices, not only in the ipsilateral
(Figure. 2.4c; 79.85 ± 7.35%; P < 0.05 compared to Sham) but also the contralateral
(Figure. 2.4d; 74.05 ± 4.13%; P < 0.05 compared to Sham) dorsal horns, with no change
in the EC50 (ipsilateral: 0.25 ± 0.07 µM, contralateral: 0.29 ± 0.04 µM; both P > 0.05
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compared to Sham). These data illustrate that injury increases the membrane availability
of functional MORs in the dorsal horn.
Third, the antinociceptive effects of

intrathecal DAMGO were potentiated in

CFA-21d mice (Figure. 2.4e; P < 0.05, Student’s t Test), which further suggests
increased MOR number. Fourth, as illustrated in Figure 2.3f, intrathecal injection of PheCys-Tyr-Trp-Orn-Thr-Pen-Thr-NH2 (CTOP), a MOR-selective antagonist, reinstated
hyperalgesia in CFA-21d (F3,20 = 9.83, P < 0.0005) and CFA-105d (F3,10 = 9.87, P =
0.0025; [same data as shown in Figure 2.2d]) mice but not sham controls. Taken
together these findings demonstrate that upregulated tonic MOR-G-protein signal
transduction persists after the resolution of inflammatory hyperalgesia, and mediates
long-lasting endogenous antinociception that opposes the emergence of chronic
hyperalgesia.
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Figure 2.4. The functional capacity of spinal µ-opioid receptor coupling to Gproteins is increased after injury.
(a) Effect of intrathecal PTX (0.2 µg) on mechanical thresholds 21d after sham and CFA
injuries.  P < 0.05 compared to Sham + PTX. (n = 4 - 6 per group) (b) Representative
pseudo-color and (c,d) dose-response effects of DAMGO-stimulated GTPγS35 binding as
compared to basal binding in Sham and CFA-21d lumbar spinal cord slices; (c)
ipsilateral and (d) contralateral dorsal horns; insets: group binding Emax. (n = 7 – 9). (e)
Antinociceptive effects of intrathecal DAMGO in sham and CFA-21d mice on a 56ºC
hotplate (n = 8 per group).  P < 0.05. (f) Effect of intrathecal CTOP (100 ng) on
mechanical thresholds at 21d (left; n =5-7) and 105d (right; n = 3-5) post CFA and sham.
 P < 0.05 compared to Sham. Data in panels b-d was collected by Greg Corder,
Michelle Winter and Kenneth McCarson; see Methods for specific contributions. Data
shown as mean ± s.e.m.
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2.3.5. Spinal μ-opioid receptors inhibit a latent central sensitization that persists in the
post-hyperalgesic state.
Opioids inhibit central sensitization in the dorsal horn (Terman et al., 2001)
(Benrath et al., 2004), but whether this can be maintained for long periods of time to
impinge on chronic pain in unknown. Phosphorylated extracellular signal-regulated
kinase (pERK) is implicated in the spinal transduction of nociceptive signals and serves
as a marker of central sensitization during pathological conditions (Ji et al., 1999; Ji et
al., 2009). We found that compared to shams, innocuous light-touch of the injured
hindpaw did not increase pERK expression 21 days after CFA in the dorsal horns
(Figure. 2.5a and 2.5b). However, intrathecal NTX increased touch-evoked pERK in
lamina I-II (NTX, 15.1 ± 3.5 cells; saline, 5.2 ± 2.6 cells; P < 0.05; Figure. 2.5a and 2.5b)
and III-V (NTX, 5.3 ± 1.7 cells; saline, 1.8 ± 1.3 cells; P < 0.05; Figure. 2.5a and 2.5b).
Ipsilateral touch stimulation after NTX also increased pERK at the contralateral dorsal
horn (7.34 ± 1.37 cells per slice, P < 0.05; Figure. 2.5b and 2.5c and 2.5d). Confocal
microscopy revealed that pERK was expressed on many NeuN-positive profiles within
the tibial nerve innervation zone of the medial dorsal horn (Figure. 2.5e). pERK positive
structures were not co-localized with markers of spinal microglia or astrocytes (Figure
2.6). These results reveal the presence of sensitized spinal nociceptive neurons that
outlast the resolution of hyperalgesia and remain under the control of endogenous MOR
inhibitory mechanisms. These findings are consistent with previous work suggesting that
stress (Rivat et al., 2007) or injury (Rivat et al., 2002) escalates opposing inhibitory and
excitatory influences on pain processing.
We noted residual edema of the CFA paw at 21d (Figure 2.2a); therefore we
hypothesized that the NTX-induced hyperalgesia and pERK results from disinhibition of
on-going primary afferent activity from the inflamed tissue. To test this hypothesis, we
systemically eliminated possible sources of activity coming into the spinal cord and then
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quantified the number of pERK positive cells in the dorsal horn as a measure of spinal
nociceptive pathway activity. To ensure mechanical stimulation of the injured paw, 21dCFA mice were allowed to walk, unrestrained, on a metal-mesh grate for 30 min
(Ambulation). We found no difference in pERK expression compared to sham mice
allowed to ambulate on the same surface (Figure 2.5f). However intrathecal NTX prior to
ambulation significantly increased pERK expression in the ipsilateral and contralateral
dorsal horns (Figure 2.5f). This hints that NTX may disinhibit sensitized Aβ-fiber circuits
since innocuous ambulation, just like the light-touch protocol above, produces activity in
spinal laminas I and II. Therefore to eliminate stimulus-induced activity we anesthetized
the mice with light isoflurane anesthesia, to prevent walking and joint-movement. This,
however, did not prevent NTX-induced increases in spinal pERK levels (Figure 2.5f);
suggesting NTX may disinhibit tonic, non-evoked, afferent activity. We further assessed
afferent activity by combining anesthesia with a lidocaine sciatic nerve block prior to
NTX. However, with afferent input removed we found significant pERK expression
(Figure 2.5f; P < 0.05). Local anesthesia did not change pERK expression. The pERK
profiles were clustered in lamina I neurons only, with little to no pERK+ cells in deeper
laminas. Together, these data suggest that removal of inhibitory opioid receptor
signaling produces neuronal activity, within spinal nociceptive pathways, independent of
primary afferent drive.
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Figure 2.5. Blockade of spinal opioid receptor signaling reveals sensitization in a
subset of dorsal horn neurons that respond to innocuous light-touch stimulation
or become active independent of primary afferent activity.
(a) Representative images and (b) laminar quantification (I-II and III-V) in ipsilateral and
contralateral dorsal horn of immunoreactive cells for pERK in sham and CFA-21d mice
given light mechanical touch of the injured paw 30 min after intrathecal saline or NTX
(1µg). (n = 5 - 7). (c) Representative pseudo-colored light-microscope image and (d)
confocal image of the same pERK positive cells in the ipsilateral and contralateral dorsal
horns from a mouse given light touch + NTX. (e) From boxed region in panel d: Co54

localization of pERK with NeuN. (f) left: quantification of dorsal horn pERK cells from
NTX-treated mice walking on a metal grate (Ambulation), not moving or walking
(Anesthesia; 2% isoflurane), and/or injected with 2% lidocaine (100 µl) into the popliteal
fossa (Sciatic nerve block). Right: effect of popliteal fossa lidocaine injection on
intraplantar capsaicin-induced (10 µg in 5 µ) spinal pERK expression. All scale bars =
200 µm. P<0.05;  P < 0.05 compared to all groups. All data shown as mean ± s.e.m.

55

Figure 2.6. Light-touch evoked spinal pERK is co-localized within neurons but not
astrocytes or microglia.
Representative spinal cord sections (30 μm) from CFA-21d mice given intrathecal NTX
(1 μg) and an ipsilateral light-touch paw stimulation (see Supplementary Methods) were
co-stained for phosphorylated extracellular regulated kinase (rabbit, 1:700 Cell
Signaling) and either (A-C) NeuN::Alexa-488 (rat, 1:200, Millipore; confocal images
taken at 5x; inset: 40x), GFAP (rat, 1:5000, Invitrogen; light microscope images taken
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at 10x for panels D-F and 40x for panel G) or CD11b (rat, 1:5000, AbD Serotec; light
microscope images taken at 10x for panels H-J and 40x for panel K). All scale bars are
200 μm. Panels A-C are from the same spinal cord slice shown in Fig. 1T-W.
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2.3.6. Opioid receptor blockade reinstates hyperalgesia in a model of transient
neuropathic pain
Up to this point we have demonstrated that opioid and nociceptive-facilitatory
mechanisms persist in the complete Freund’s adjuvant (CFA) model of inflammation for
up to 200 days after the initial injury. In many inflammation models opioid peptide and
receptor expression are upregulated (Goff et al., 1998) (Calza et al., 2000). Yet studies
using nerve injury models of neuropathic pain often report decreases in opioid receptor
expression or de-coupling of inhibitory G-proteins from MORs, which would suggest
decreased endogenous analgesic relevancy for spinal MORs. Therefore to determine
whether NTX can reinstate hypersensitivity not only in the setting of inflammation but
also in the setting of nerve injury, we performed comparable studies after transection of
the common peroneal and tibial branches of the sciatic nerve (CPxSx) (Figure 2.7), as
described by Solway et al. (2011). In contrast to the spared nerve injury model of
neuropathic pain, which produces a long-lasting “floor” in mechanical von Frey
thresholds, the CPxSx nerve injury model induces hyperalgesia that lasts for just a few
weeks. As illustrated in Figure 2.7a, CPxSx produced mechanical hyperalgesia that
began to resolve around day 14, and was fully resolved by day 21. CpxSx did not
produce cold allodynia (Figure 2.7c). As detailed in Figures 2.6b and 2.6d, NTX (10 ug,
i.t.) reinstated tactile hypersensitivity (F3,28 = 4.95, P < 0.005) and induced cold
hypersensitivity (F3,28 = 12.91, P < 0.0001). By contrast, neither peripherally restricted
NMB nor saline (s.c. or i.t.) produced alterations in tactile sensitivity (P > 0.05).
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Figure 2.7. Blockade of spinal opioid receptor signaling reinstates hyperalgesia in
a model of transient neuropathic pain.
(a and c) Progression and recovery of Spared Nerve Injury variant surgery (CPxSx) (n =
44) induced (a) mechanical hyperalgesia and (c) cold allodynia. (b and d) Effect of
intrathecal NTX (1µg) or saline, and subcutaneous NMB (3 mg/kg) or saline on (b)
mechanical thresholds and (d) duration of paw withdraw from an acetone drop.  P <
0.05 compared to all groups. All data shown as mean ± s.e.m. (Assistance with behavior
was provided by Amanda Webb).
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2.4 Discussion
2.4.1. Long-lasting endogenous opioid analgesia
Endogenous opioid inhibition of acute nociception persists even after the initial
signs of hyperalgesia have subsided (Yu et al., 1994; Li et al., 2001; Guan et al., 2010;
Joseph et al., 2010; Campillo et al., 2011a). This is demonstrated by the ability of opioid
receptor antagonists to precipitate allodynia in the post-hyperalgesic state. In extension
of these works, we found withdrawal frequencies to mechanical stimuli were unaltered
by NTX in wild-type sham mice, consistent with observations in normal μ-opioid receptor
knock-out mice that do not show changes in acute nociceptive processing (Fuchs et al.,
1999). Similar studies in normal human subjects also report no modulation of pain
perception upon opioid antagonist treatment, suggesting little to no tonically active
endogenous opioid signaling in the absence of tissue or nerve damage (El-Sobky et al.,
1976; Schoell et al., 2010). The contribution of endogenous opioid tone to transient pain
or acute inflammatory pain is weak at best, as opioid receptor antagonists do not
increase pain during cold, thermal or formalin acute testing (Taylor et al., 1997; Grevert
and Goldstein, 1978; Kern et al., 2008). Under chronic pain conditions, however, opioid
mechanisms are thought to be recruited in response to intense, sustained nociceptive
signaling (Levine et al., 1978; Mansikka et al., 2004).
We found that CFA inflammatory pain progressively recovered. This is
demonstrated by the return of mechanical withdrawal thresholds to pre-injury levels. This
suggests that pain recovery results from either deactivation of pronociceptive systems or
increased counter-adaptive endogenous inhibition. By ablating the initial pain recovery
with continuous NTX infusion (Figure 2.1b), we demonstrated that the endogenous
opioid system is activated after CFA to dampen persistent nociception.
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Several explanations for this finding can be proposed: strong noxious input is
accompanied by the release of opioid peptides, increased opioid receptor density, and
enhanced G-protein coupling in the spinal cord (Yaksh and Elde, 1981; Basbaum and
Fields, 1984; Iadarola et al., 1986; Noguchi et al., 1992; Calza et al., 2000; Mousa et al.,
2002; Song and Marvizon, 2003; Schepers et al., 2008b; Goff et al., 1998; Shaqura et
al., 2004). Interestingly we find that augmentations in spinal MOR-G-protein coupling last
for at least 3 weeks after CFA even though the initial bout of allodynia is completely
absent, suggesting that opioid signaling did not dissipate.
In support of the hypothesis that increases in opioid receptor expression and
function facilitate endogenous analgesia we show that disruption of Gαi/o activation with
intrathecal pertussis toxin precipitated hyperalgesia. Moreover, pharmacological
blockade of opioid receptor signaling with systemic or intrathecal NTX reinstated
mechanical and thermal hyperalgesia. Remarkably we could reinstate pain behaviors for
up to 105 d after the injury, while tissue inflammation had recovered by 49d. Others have
demonstrated that opioid receptor density in the superficial spinal cord progressively
increases over days to weeks during chronic inflammation states and is suggested to aid
in the analgesic effectiveness of exogenously applied opiate drugs (Ji et al., 1995; Goff
et al., 1998; Mousa et al., 2002). An autoradiographic study showed that opioid receptor
density can remain greatly elevated 79 d after CFA tail-vein injection when pain scores
had recovered to baseline (Calza et al., 2000). Collectively, our data illustrates the
presence of persistent pronociceptive and opioidergic plasticity that outlasts not only
acute pain, but the physical injury as well.
It is likely the case that the endogenous opioidergic system is not the sole
promoter of endogenous analgesia. Other endogenous inhibitory systems, including the
endocannabinoids (Alkaitis et al., 2010) and resolvins (Ji et al., 2011), reduce both
nociception as well as inflammation. Additionally, our lab has recently shown that the
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endogenous Neuropeptide Y system is also involved in recovery from inflammation and
neuropathic pain (Solway et al., 2011). Therefore it is likely that endogenous MORs work
in concert with numerous neuromodulatory systems to reduce nociception and aid in the
resolution of pain.
2.4.2. No evidence for peripheral opioid effects in mediating long-lasting endogenous
analgesia
Shortly after the induction of inflammation with intraplantar CFA, immune cells
(granulocytes and monocytic cells) extravagation into the inflamed tissue is mediated, in
part, by strong central nociceptive signal activation of intercellular adhesion molecules
(e.g. ICAM-1 and β-integrin) (Machelska et al., 2002). Stimulation of Toll-like receptors
causes the immune cells to release endorphin and enkephalin which act upon the µ- and
δ- opioid receptors on nerve fibers innervating the inflamed tissue (Rittner et al., 2009).
We found the paw thickness of CFA injured animals was maximal 7 days after CFA
(50% increase from baseline thickness), while at the same time mechanical thresholds
began to recover. On day 21, when pain behaviors had fully resolved, paw thickness
decreased 11.25% from the day 7 measurements. It is likely that the mineral
oil/mycobacterium emulsion was not cleared from the tissue as paw thickness remained
elevated for 49 days compared to Sham controls.
With the use of the BBB-impermeable drug, NMB, we were able to localize opioid
antagonism to either peripheral receptors in the nerve endings and DRG somata by
subcutaneous injection, or to CNS receptors in the spinal cord by intrathecal injection.
Lack of pain reinstatement with systemic NMB 21d after CFA suggests that peripheral
opioid signaling does not contribute to the inhibition of latent nociceptive sensitization.
Spinal intrathecal injection of NMB, however, produced robust reinstatement of
mechanical hypersensitivity comparable to the systemic and intrathecal effects of NTX.
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This suggests that it is the central opioid receptors that are responsible for long-term
endogenous analgesia. Previous work has shown i.c.v. NMB was able to attenuate
conditional analgesia in the formalin test but has no effect when delivered i.p.
(Calcagenetti et al., 1987).
In contrast to the findings presented in this dissertation it was reported that
peripheral opioids are exclusively responsible for endogenous analgesic mechanisms
96-144 hours after the induction of inflammation (which the authors describe as “later
stage of inflammation”) (Stein, 2003). These studies evaluated spinal opioid contribution
6 days post-CFA by “low doses” (as claimed by the authors) of naloxone hydrochloride
(1.125 μg) injected at the site of inflammation (e.g. injected directly into the inflamed
tissue) that are presumed to “not enter systemic circulation or the central nervous
system”. They do not, however, report using higher, centrally acting doses of naloxone
HCl and therefore do not entirely validate their claim. Nonetheless, peripheral opioid
signaling may be important for the immediate resolution of pain (several days after the
injury, as shown by Stein and colleagues), but long-term maintenance of the
endogenous analgesia (21 days and beyond, as we have demonstrated in this
dissertation) appears to reside largely in the spinal cord and CNS.
2.4.3. Endogenous opioidergic analgesia occurs in the spinal cord
We further localized these persistent opposing processes (i.e. opioid signaling
and latent nociceptive mechanisms) to the lumbar spinal cord by visualization of pERK in
the dorsal horn nociceptive circuitry. pERK is typically observed following high-threshold
(Aδ- or C-fiber) or noxious stimulation (Ji et al., 1999), however, during the maintenance
phase of chronic pain (> 2 days post CFA) a low-threshold (Aβ-fiber) stimulation
(Matsumoto et al., 2008) or light-touch (Gao and Ji, 2010) can induce spinal pERK
expression, suggestive of injury-induced central sensitization (Ji et al., 2003). We found
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that after pain resolution (21d), light-touch is unable to effectively activate superficial
dorsal horn neurons unless the latent sensitization is disinhibited by NTX, indicating that
opioid signaling actively represses signal amplification, similar to spinal GABAergic
signaling (Baba et al., 2003; Torsney and MacDermott, 2006; Torsney, 2011). The
expression of pERK, and thus central sensitization, was not reliant on on-going activity
of the primary afferent as sciatic nerve block did not ablate neuronal activation in
laminas I and II, providing additional support for this CNS site of action. The presence of
pERK in the substantia gelatinosa suggests that the latent sensitization and tonic MOR
signaling may exist in NK1-R expressing projection neurons or interneurons (inhibitory or
excitatory). Future studies will be required to determine the exact neuronal population
that MOR signaling occurs (immunohistochemical or electrophysiological phenotyping).
Either this latent nociceptive sensitization is maintained within the local spinal
circuitry (Ruscheweyh et al., 2011) or is partially maintained by descending facilitatory
signals from brainstem or cortical nuclei (Porreca et al., 2002). At this point we cannot
rule out the contribution of supraspinal regions believed to store the memory of pain
such as the anterior cingulate cortex or amygdala (please see Chapter 3 for evidence
and discussion of supraspinal opioidergic circuits. Also see Chapter 2 Discussion section
2.4.4. Contralateral effects.

However, hyperalgesic priming models suggest a “pain

engram” is encoded in the spinal cord (Asiedu et al., 2011a), revealed as a potentiated
pain response to a second injury or stressor. Our study suggests that intrathecal MOR
antagonists disinhibit these excitatory spinal processes. This further illustrates a
homeostatic reduction by increased endogenous opioid tone. In agreement, others have
suggested this concept of counter-inhibition of nociceptive plasticity whereby opioid
receptor antagonists precipitate pain-like responses under different pathological states
(Yu et al., 1994; Back et al., 2006; Sevcik et al., 2006; Guan et al., 2010; Campillo et al.,
2011b).
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2.4.4. Contralateral effects
Interestingly, in the contralateral dorsal horn we also found increased MOR-Gprotein GTPγS35 binding (Figure 2.4d) and NTX-induced neuronal activation (i.e. pERK+
cells; Figure 2.5b), illustrating the spread of central sensitization and increased opioid
signaling, to uninjured areas of the CNS. This possibly accounts for the NTX-induced
“mirror pain” in the uninjured paw (Figure 2.3b). The development of acute hindpaw
hypersensitivity is not merely a side specific occurrence but rather a bilateral
phenomenon. Contralateral mechanical sensitivity is also reported in numerous pain
models (inflammation (Chillingworth et al., 2006), nerve injuries (Kim and Chung, 1992)
(Seltzer et al., 1990), formalin (Aloisi et al., 1993), arthritis (Rees et al., 1996) , sciatic
inflammatory neuritis (Chacur et al., 2001), and muscle pain (Sluka et al., 2001;
Ainsworth et al., 2006). Bilateral sensitivity has been discussed for years and several
theories have been postulated involving spinal interneurons, astrocyte gap-junction
networks, or top-down facilitation from the brainstem (For review see: (Koltzenburg et
al., 1999) and (Cao and Zhang, 2008)), although a definitive cause remains elusive.
However the lack of NTX-induced pERK (a marker of cellular activity and central
sensitization) in microglia and astrocytes suggests that lasting sensitization does not
occur in this cell type and these cells are not activated upon loss of tonic MOR signaling.
Whether this long-term neuroadaptation is strictly localized to the spinal cord or
supraspinal

regions

remains

unclear.

Persistent

inflammation

increases

the

effectiveness of exogenously applied opioid agonists to inhibit contralateral nociceptive
sensitivity in the RVM (Schepers et al., 2008a) and the spinal cord (Stanfa and
Dickenson, 1995). Our opioid receptor antagonist injections into the spinal cord (Figure
2.3) or into the brain (i.c.v. drug injections: Chapter 3, Figure 3.9) also suggest adaptive
enhancement modifications have taken place in both regions of the CNS.
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2.4.5. Endogenous opioidergic analgesia negatively regulates neuropathic pain
Spinal intrathecal NTX injections increased mechanical and cold hypersensitivity
in the CPxSx model of neuropathic pain. In the Spared Nerve Injury and Sciatic Nerve
Ligation models of neuropathic pain, expression of spinal MORs are reported to be
dramatically decreased in those areas where primary afferents have been injured,
(Porreca et al., 1998; Kohno et al., 2005; Corder et al., 2010). It would seem that loss of
MOR would be associated with hyperalgesia. But instead, we observed endogenous
analgesia over our 21 day recovery period. DeGroot et al. (deGroot et al., 1997) saw a
return of MOR expression 31 days following peripheral axotomy that was equal to the
uninjured contralateral dorsal horn, which suggests possible recovery of spinal MOR
inhbitory function. This could explain the natural resolution of neuropathic pain we
observed.
Another study showed, two weeks after spinal nerve ligation, that a decrease in
MOR immunostaining correlated with the development of hyperalgesia in rats, while nonallodynic rats did not exhibit a loss in spinal MOR expression.

Those non-allodnic

animals were given systmic naloxone HCl or intrathecal CTOP, which produced
hyperalgesia. This suggests that loss of spinal MORs dictates the degree of neuropathic
pain (Back et al., 2006). Similar suggestions on the importance of spinal MOR
expression levels have been made when investigating the severity of injury to peripheral
nerves. For example, the hyperalgesia accompnaying damage to the larger tibial and
common peroneal nerves does not recover (TxCPx). Whereas damage to the sural and
common peroneal nerves displays a transient and recoverable neuropathic pain
phenotype (SxCPx). Additionally, partial nerve ligation produces similar transient
mechanical hyperalgesia compared to a full nerve ligation (Guan et al., 2010). The
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shorter duration of hyperalgesia in the SxCPx model might represent a lesser decrease
in MOR expression or function in the dorsal horn.
2.4.6. Future Studies
1. As illustrated in Figure 2.4f, spinal MORs mask latent sensitization: CTOP (i.t.,
100ng) reinstated hypersensitivity 21 and 105d after CFA. However, the contribution of
the δ- and κ- opioid receptor subtypes, in promoting long-lived endogenous analgesia,
has not been tested. Future studies could administer selective blockers for μ (CTOP), δ
(naltrindole), and κ (nor-binaltorphimine) opioid receptors to determine which receptors
mediate long-lasting endogenous analgesia. It is important to note that the 100 ng of
CTOP dose used in this dissertation is a high dose, and potentially interacts with δOR
(personal communication with Dr. Gregory Scherrer). To test selectivity, a full doseresponse curve should be generated for each opioid receptor blocker.
During inflammation and sustained pain conditions, δORs contained within largedense-core-vesicles are functionally inserted into the plasma membrane (Cahill et al.,
2003; Bao et al., 2003; Walwyn et al., 2005; Guan et al., 2005). Thus, δORs may
contribute to long-term analgesia in our model. Therefore, a logical prediction is that
naltrindole will reinstate hypersensitivity. In addition, blockade of spinal κORs with norBIN and genetic deletion of κOR enhanced CFA-induced hypersensitivity (Schepers et
al., 2008) and nor-BIN reinstated mechanical hypersensitivity in a model of postoperative pain (Campillo et al., 2011). Therefore, a further prediction is that blockade of
spinal κORs in our model will reinstate mechanical/heat hypersensitivity. These are
important areas for future investigations.

2. In humans, males and females are differentially affected by chronic pain
(Unruh, 1996; Greenspan et al., 2007). Male mice were exclusively used throughout all
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studies in this dissertation. Therefore, the use of male and female mice to explore sex
differences, in relation to prolonged endogenous analgesia, remain a critical hypothesis
to test.
It will be important to consider the effects of the estrous cycle on endogenous
opioid analgesia. Human female studies have shown that low estradiol (E2) correlates
with decreased MOR activity and increased pain sensitivity (Smith et al., 2006), whereas
experimental high E2 conditions correlate with enhanced opioid peptide release and
receptor activation (Zubieta et al., 2002). E2 administration, in ovariectomized rodents,
has been shown to increase MOR expression (Hammer et al., 1987; Dondi et al., 1992;
Quinones-Jenab et al., 1997), opioid peptide expression (Broad et al., 1993; Hammer et
al., 1993) and release (Eckersell et al., 1998). On this basis, we would predict that
female mice will not recover sensory thresholds as quickly, or fully, as males. We could
also predict that spinal NTX will be effective at unmasking latent sensitization females.
However, this prediction is tentative for several reasons such as: a large body of
literature argues that estrogens are pronociceptive (Levine et al., 1989; Aloisi et al.,
2000; Craft et al., 2004); there are no sex differences in spinal MOR expression (Ji et al.,
2006); male basal MOR expression is higher in the PAG (Loyd et al., 2008); and
exogenous opioids are more effective at relieving pain in male rodents and humans
(Cepeda et al., 2003; Miller et al., 2004).
Study limitations or confusion in data interpretation could result from findings
demonstrating that, indeed, physical insult (e.g. i.pl CFA (Battisto et al., 1967)) and
stress compromises menstrual cyclicity (Harlow et al., 1991; Bonen, 1994; Carpenter,
1994). The CFA could arrest female mice in diestrous, a period of low estrogens
(Battisto et al., 1967).
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3. In several pilot studies, myself and other members of the Taylor lab (Justin
Pinson, Jennifer Grasch, Amanda Webb, and Ryan Griggs), attempted to visualize the
spinal MOR population using immunohistochemistry. However, the anti-MOR antibodies
from Neuromics (product # RA10104 and GP10106; 1:250 – 1:2000) and ImmunoStar
(product # 24216; 1: 500 – 1:1000) produced high background and staining patterns not
fully consistent with MOR in situ hybridization studies (i.e. intense positive staining
throughout the spinal cord gray matter) (Matthes et al. 1996). Future studies should
attempt a broader range of antibody concentrations (1:2000 and greater), to test
selectivity. However, via a personal communication, these same antibodies have been
reported to show some positive staining in MOR KO mouse brains and large amounts of
diffuse staining within the dorsal root ganglia cell cytoplasm of wild-type mice (MOR, like
other GPCRs, is present mostly on the cell membrane) (personal communication with
Gregory Scherrer and Allan Basbaum). Therefore new antibodies should be investigated
or created, and tested against MOR KO mice to ensure selectivity. Additionally, future
studies could involve the use of alterative quantitative methods to assess MOR
expression levels throughout the course of CFA hyperalgesia and into the posthyperalgesic state. More sensitive techniques that could be explored include
radiographic studies utilizing radio-tagged ligands (the radio-tag signal can be quantified
as a measure of functional binding pockets (e.g. more binding pockets indicates
increased MOR levels)), qRT-PCR, or in situ hybridization.
4. The predominant presence of pERK in the substantia gelatinosa (laminas I-II)
suggests that the latent sensitization and tonic MOR signaling may exist in NK1-R
expressing projection neurons, excitatory (PKCγ or calbindin populations), or inhibitory
(GABAergic) interneurons. Future studies, using immunohistochemical co-expression
experiments, will be required to determine the exact neuronal subpopulations in which
tonic MOR signaling and latent sensitization occur.
69

5. The lack of NTX-induced pERK in astrocytes or microglia (Fig 2.6) suggests
that the maintenance of lasting sensitization does not occur in these cell types. However
this does not exclude astrocytes or microglia from participating in the induction of latent
sensitization. Future studies could pharmacologically block glia function during the first 3
weeks of the CFA injury (e.g. minipump infusion of minocycline or fluorocitrate), then
assess the ability of NTX to produce hyperalgesia and spinal pERK.

Copyright © Gregory F. Corder 2013
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CHAPTER 3

Tonic opioid receptor signaling contributes to the persistence of central
sensitization by producing psychological and physical opioid dependence

3.1. Introduction
The data provided in Chapter 2 suggests that NTX disinhibits an underlying
nociceptive sensitization, arguing that both opioidergic and pronociceptive systems did
not subside after injury recovery. Indeed, a long-lasting balance between opioidergic and
NMDA-R activity was demonstrated following chronic environmental stress (Le Roy et
al., 2011) or injury (Rivat et al., 2002; Rivat et al., 2007). Although never fully
investigated beyond mere behavioral pharmacology studies, this excitation/inhibition
balance was suggested to result from a pathological consequence of increased
endogenous opioid tone after the stress or insult.
How might long-lasting MOR signaling contribute to the persistence of
pathological nociceptive plasticity or the latent central sensitization? Neuroadaptations
result from prolonged exogenous opioid exposure, specifically compensatory increases
in the expression of Ca2+-sensitive adenylyl cyclases, AC1 and AC8 (Lane-Ladd et al.,
1997). These cellular mechanisms are hypothesized to promote drug addiction and
prolonged physical dependence.

Such augmentations are revealed during opioid

withdrawal and produce cAMP overshoot (AC superactivation), leading to excitatory
synaptic plasticity.
AC1 is expressed in the post-synaptic density of central neurons (Xia et al.,
1991; Conti et al., 2007), in the brain and the superficial dorsal horn (Wei et al., 2002),
and is subject to negative regulation by Gαi/o-coupled receptors in vivo (Nielsen et al.,
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1996). Functionally, AC1 links NMDA-R-derived Ca2+ increases to cAMP signaling
pathways (Chetkovich and Sweatt, 1993; Wong et al., 1999) necessary for LTP initiation
(Wang and Zhuo, 2002), opiate physical dependence (Zachariou et al., 2008) and spinal
synaptic facilitation (Wei et al., 2006; Wang et al., 2011). AC1 has a prominent role in
chronic pain (Wei et al., 2002) and, mechanistically, may facilitate the phosphorylation
and insertion of synaptic GluR1 (Xu et al., 2008) via PKA and/or PKMζ (Li et al., 2010;
Asiedu et al., 2011a; Zhuo, 2012) to increase synaptic strength during LTP. It has been
demonstrated that withdrawal from exogenous opioids results in synaptic LTP in spinal
neurons and relies on post-synaptic NMDA-R Ca2+ mobilization to mediate the
hyperalgesia associated with physical withdrawal (Drdla et al., 2009).
I hypothesize that prolonged endogenous-mediated MOR signaling drives the
upregulation of the spinal adenylyl cyclase system in an analogous manner to opiate
cellular dependence, thereby promoting the maintenance of latent central sensitization.

3.2. Methods and Materials
3.2.1. Mice:

At the beginning of all experiments the subjects were naïve, adult (6-10

weeks for behavioral and biochemical studies; 3-4 weeks for Ca2+ imagining studies),
male C57Bl/6 (Charles River), AC1 - /-, or littermate AC1+/+ wild-type controls. All
procedures were approved by the Institutional Animal Care and Use Committee at the
University of Kentucky in accordance with American Veterinary Medical Association
guidelines.
AC1-/- mice and AC1+/+ mice, bred congenic onto a C57Bl/6 background, were provided
by Dr. Daniel Storm (University of Washington, Seattle, WA, USA). Renee Donahue
maintained the line using heterozygous breeding and the genotype was confirmed by a
tail-snip PCR.
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As originally characterized by Xu and Storm (1995), generation of AC1 KO mice was
performed as follows:

A gene targeting vector was constructed and used for

homologous recombination in ES cells. A mouse AC1 genomic clone, ZX3 (14.5 kb),
encoding the N-terminal 210 amino acids of I-AC was isolated from a genomic library
(OLA 129). The gene-targeting vector, 1126, was constructed by replacing a 0.5-kb Nar
I-Pst I fragment of ZX3, which includes the coding region for the first 140 amino acids of
AC1, with neo’ cassette. Then, a herpes simplex virus thymidine kinase gene was added
to one end of the vector. An ES cell clone was injected into C57BL/6 blastocysts to
generate chimeric mice. Male chimeric mice bred with C57BL/6 females to produces
heterozygotes that were subsequently inbred to produce homozygous mutant mice.
Mice were housed in plastic cages (bedding and enrichment) of 4 same-sex littermates
in a temperature controlled environment (14 hr: 10 hr light-dark cycle; lights on at 7:00
am) with ad libitum access to food and water. Upon arrival to the University of Kentucky
Division of Laboratory Animal Resources, mice were habituated to the colony housing
room for 1 week prior to any experimentation.
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Table 3.1. Animal use quantification for figures 3.1 – 3.11.
Figure

3.1a

Group n at
start of
experiment

Group n
reported in
analysis and
figures

Comments on mouse
removal

Date of
experiment
(month,
year)

--

Naïve: 2
3d Sham: 4
3d CFA:5
21d Sham:5
21d CFA:7

Only slices that displayed a
consistent control response to 1
mM glutamate at the beginning and
end of the experiment (showing a
less than 40% decrease in
glutamate-evoked Ca2+ transients)
were included in this study.

2012

n/a

2012

n/a

2011

n/a

2012

n/a

2012

Control groups (‘Sham+vehicle’
and ‘CFA+vehicle’) were combined
from the two experiments

2012

Saline: 5
MK-801: 5
NTX: 5
MK-801+NTX: 5

--

2012

AC1-/-: 9
AC1+/+: 4

These were the only available mice
provided by Dr. Daniel Storm (U.
Washington)
--

2012

3.1b

--

3.1d,e

--

3.2a,b

Sham: 6
CFA: 6
Sham: 5
CFA: 5
Exp. 1:
Sham+vehicle:
6
Sham+CTOP:
6
CFA+vehicle:
6
CFA+CTOP: 6

3.2c,d
3.2e

3.2f

3.3a-c

3.3d

Exp. 2:
Sham+vehicle:
8
Sham+NTX: 6
CFA+vehicle:
11
CFA+NTX: 10
Saline: 5
MK-801: 5
NTX: 5
MK-801+NTX:
5
AC1-/-: 9
AC1+/+: 4
Vehicle+NTX:
5
NB001+NTX:
7

1-2 spinal cord
slices were used
from each animal.
Sham+NTX: 3
CFA+NTX: 4
Sham+CTOP: 4
CFA+CTOP: 5
Sham+NTX+MK801: 5
CFA+NTX+MK-801:
6
Vehicle+vehicle: 5
Vehicle+NTX: 5
MK-801+vehicle: 7
MK-801+NTX: 9
Sham: 6
CFA: 6
Sham: 5
CFA: 5
Sham+vehicle: 14
Sham+CTOP: 6
Sham+NTX: 6
CFA+vehicle: 17
CFA+CTOP: 6
CFA+NTX: 10

Vehicle+NTX: 4
NB001+NTX: 7
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2012

Table 3.1 (continued)

3.3e

3.5a,b

3.5c,d

3.6a-f

--

Saline: 6
NTX: 8
NB001+NTX: 9

n/a

2012

Sham+naloxon
e: 6
CFA+saline: 6
CFA+naloxone
:6
Naloxone: 6
Naloxone+NB
001: 6
--

Sham+naloxone: 6
CFA+saline: 6
CFA+naloxone: 6

n/a

2012

Naloxone: 6
Naloxone+NB001: 6

n/a

2012

1d:
Sham:saline: 6
Sham:NTX: 5
CFA:saline: 6
CFA:NTX: 6
3d:
CFA:saline: 5
CFA:NMB: 6
CFA:NTX: 6
21d:
CFA:saline: 6
CFA:NMB: 6
CFA:NTX: 7
CFA 1d:8
CFA 3d: 8
CFA 21d: 7
CFA 49d: 7
CFA 77d:6
CFA+NTX: 6
CFA+vehicle: 6
Sham+NTX: 6
Sham+vehicle: 6

n/a

2009

- loss of mice resulted from death
by littermate fighting

2009

n/a

2010

CFA+vehicle: 14
CFA+CTOP 100ng:
7
CFA+CTOP 300 ng:
12
CFA+B-FNA: 9

n/a

2012

Sham: 7
CFA: 8

Mouse found dead in home cage
on day 3. Exact cause unknown.
Possible effect of morphine.

2012

and
3.7a-d

3.8

3.9a, c-e

3.9b, c-e

3.10a-e

8

CFA+NTX: 6
CFA+vehicle:
6
Sham+NTX: 6
Sham+vehicle:
6
--

Sham: 8
CFA: 8

Unknown information is denoted by dashed lines (--).
Information that is not applicable is denoted as n/a
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3.2.2. Complete Freund’s Adjuvant (CFA) model of inflammatory pain:

please refer to

section 2.2.2, page 30.
3.2.3. Mouse (in vivo) drug administration:

For subcutaneous injections and intrathecal

injection methods please refer to section 2.2.4, page 30. For intracerebroventricular
injection of drugs, guide cannula (Plastics one, Roanoke, VA) were placed 14d after
CFA.

Surgical anesthesia was achieved with isoﬂurane (5% for induction; 1.5e2% for

maintenance). Anesthetized mice were placed in a stereotaxic apparatus ﬁtted with blunt
ear bars (Stoelting, Kiel, WI). After an incision to expose the cranium, the dorsal surface
of the skull was leveled by zeroing the dorso-ventral coordinate at lambda and bregma.
A 26-G stainless steel guide cannula (Plastics One, Roanoke, VA) was lowered to the
right lateral brain ventricle using the following stereotaxic coordinates: 0.7 posterior to
bregma, 1.5 mm lateral from midline and 3.3-4.0 mm below the skull surface (Paxinos
and Watson, 1997). Initial placement of the cannula was veriﬁed by slow downward
movement of saline when the tubing was opened and raised (Taylor et al., 1994). The
cannula was ﬁxed to the skull with 2-3 small screws and dental cement. After hardening
of the cement and suturing of the incision, a 30G stylet (Plastics One, Roanoke, VA) was
secured within the guide.
3.2.4. Drug dosing:

The following drugs and doses were used for in vivo experiments:

naltrexone HCl (NTX, gift of the NIDA Drug Supply Program; subcutaneous: 0.003 –
10.0 mg / kg / body weight, dissolved in 200 µl saline; intrathecal: 1µg in 5µl saline),
naltrexone methobromide (NMB, gift of the NIDA Drug Supply Program; subcutaneous:
3 mg/kg in 200 µl saline; intrathecal: 0.3 µg in 5µl saline), naloxone (Sigma-Aldrich;
intraperitoneal: 3 mg/kg in 200 µl saline), Phe-Cys-Tyr-Trp-Orn-Thr-Pen-Thr-NH2
(CTOP, Sigma-Aldrich; intrathecal: 100 ng in 5µl saline), pertussis toxin (Sigma-Aldrich;
intrathecal: 0.5 µg in 5µl water), (+)-MK-801 maleate (Tocris; intrathecal: 1 µg in 5µl
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water)[this dose of MK-801 was devoid of overt motor effects], NB001 (Sigma-Aldrich;
intrathecal: 2.5 µg in 5µl water), N-Methyl-D-aspartic acid (NMDA, Sigma-Aldrich;
intrathecal: 30 pmol in 5µl water), forskolin (Sigma-Aldrich; intrathecal:1.5 µg in 5µl 1%
DMSO), and [D-Ala2, N-Me-Phe4, Gly5-ol]-Enkephalin (DAMGO; Sigma-Aldrich;
intrathecal:10-30 pmol in 5 µl saline).
3.2.5. Mechanical hyperalgesia testing:

Please refer to section 2.2.6, page 32.

3.2.6. Antinociception testing: Please refer to section 2.2.9, page 33.
3.2.7. Conditioned Place Preference:The rationale and logic of these sets of experiments
were designed by Greg Corder, Zaijie Wang (university of Illinois at Chicago) and
Bradley Taylor. Ying He (University of Illinois at Chicago) performed the experiments.
The CPP apparatus (San Diego Instruments, San Diego, CA) consists of 3 Plexiglas
chambers separated by manual doors. A center chamber (6 1/4‘‘W X 8 1/8’’ D X 13 1/8‘‘
H) connects the 2 end chambers, which are identical in size (10 3/8’’ W X 8 1/8‘‘ D X 13
1/8’’ H) but can be distinguished by texture of floor (rough versus smooth) and wall
pattern (vertical versus horizontal stripes). Movement of mice and time spent in each
chamber were monitored by 4 X 16 photobeam arrays and automatically recorded in
San Diego instruments CPP software.
Preconditioning was performed 18 d after CFA injury across 3 days (days 1-3) for
30 min each day when mice were exposed to the environment with full access to all
chambers. On day 3, a preconditioning bias test was performed to determine whether a
preexisting chamber bias existed. In this test, mice were placed into the middle chamber
and allowed to explore the open field with access to all chambers for 15 min. Data were
collected and analyzed for duration spent in each chamber. Animals spending more than
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80% or less than 20% of the total time in an end chamber were eliminated from further
testing.
We used a single conditioning protocol. On day 4 (21 d after CFA), mice first
received naloxone (i.p.) + saline (i.t.) paired with a randomly chosen chamber in the
morning. 4hr later, naloxone (i.p.) + lidocaine (0.04% i.t.) was paired with the other
chamber in the afternoon. Hyperalgesia resolved within 4 hr. During conditioning, mice
remained in the paired chamber, without access to other chambers, for 15 min
immediately following saline or drug injection. On the test day, 20 hr after the afternoon
pairing (22 d after CFA), mice were placed in the middle chamber of the CPP box with all
doors open, allowing free access to all chambers. Movement and duration of time spent
in each chamber were recorded for 15 min for analysis of chamber preference.
The plasma half-life of NTX is approximately 4 hr and we have found behavioral
effects of NTX lasting 210 min after subcutaneous administration. Based on this fact we
used naloxone for all CPP experiments, due to the reported shorter half-life (~90 min),
so that two conditioning sessions could be performed, 4 hrs apart, in one day.
3.2.8. Spontaneous nocifensive behavior:

Following intrathecal injection of NMDA or

forskolin, we recorded (15 min) the duration of nocifensive behavior, defined as caudallydirected licking or biting of the limbs, tail and trunk. Time spent on genital licking or
grooming above the trunk mid-line was not scored. The number of spontaneous paw
lifts/flinches was quantified separately.
3.2.9. Phosphorylated extracellular regulated kinase (pERK) stimulation: Please refer to
section 2.2.10.1, page 33.
3.2.10. Histology and Immunohistochemistry:
34.
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Please refer to section 2.2.11, page

3.2.11. cAMP ELISA assay: Greg Corder and Dr. Brandon Jutras performed all cAMP
ELISA studies. Greg Corder analyzed all data and generated the tissue. For in vivo
detection of intracellular cAMP levels, lumbar spinal cords were rapidly dissected 30 min
after intrathecal injections. L3-L5 segments were quickly blocked, frozen on dry ice, and
stored at -80 Celsius for later use. cAMP measurements were performed using a direct
cAMP enzyme immunoassay (Enzo Life Sciences) according to the manufacturer’s
protocol (non-acetylated protocol with sensitivity = 0.39 pmol/ml).
We utilized entire lumbar spinal cord section (dorsal and ventral) for the following
reasons: 1) it was necessary to use the dorsal and ventral aspects to achieve sufficient
sample (protein) quantities to run the cAMP ELISA in duplicate as well as run a
concurrent Bradford protein assay in duplicate for each spinal cord sample; 2) only
dorsal horn neurons exhibited increased pERK expression, suggesting that the latent
central sensitization processes exist in this region; and 3) The large majority of MOR
expression is in the dorsal horn as well (Abaddie et al., 2000). Therefore, we believe that
changes in cAMP reflect events in the dorsal horn and not the ventral horn.
3.2.12. GTPγS35 binding assay:
3.2.13. Calcium imaging:

Please refer to section 2.2.12, page 35.

As previously described by Doolen et al. (2012), Dr.

Suzanne Doolen (University of Kentucky) sectioned transverse spinal cord slices (300450 μm), derived from 6 week old mice (CFA and sham injuries, and nociceptive
behavior performed by Greg Corder), and incubated them for 60 min at room
temperature with Fura-2 AM (10 μM) and pluronic acid (0.1%) in oxygenated aCSF
containing (in mM): NaCl 127, KCl 1.8, KH2PO4 1.2, CaCl2 2.4, MgSO4 1.3, NaHCO3 26,
glucose 15. This was followed by a 20 min de-esterification period in normal aCSF.
Slices were perfused at 1–2 ml/min with normal aCSF in an RC-25 recording chamber
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(Warner Instruments) mounted on a Nikon FN-1 upright microscope fitted with a 79000
ET FURA2 Hybrid filter set (Nikon Instruments) and a Photometrics CoolSNAP HQ2
camera. Relative intracellular Ca2+ levels were determined by measuring the change in
ratio of fluorescence emission at 510 nm in response to excitation at 340 and 380 nm
(200 ms exposure). Paired images were collected at 1–1.5 seconds/frame. Relative
changes in Ca2+ levels were evaluated using Nikon Elements software by creating a
region of interest over the cell body and calculating the peak change in ratio. The peak
magnitude of Ca2+ transient was expressed as difference in exposure to exogenous
glutamate compared to baseline before glutamate. The criteria for a Ca2+ response
required at least a 10% increase above the baseline ratio. Ca2+ transients were in
response to a 10 s exposure to 0.3 mM glutamate. In antagonist studies, the slice was
perfused with the antagonist for 15 min prior to and during glutamate stimulation. Only
cells that displayed a consistent control response to 1 mM glutamate at the beginning
and end of the experiment (showing a less than 40% decrease in glutamate-evoked Ca2+
transients) were included in this study.
3.2.14. Statistics:

Please refer to section 2.2.13, page 36.

3.2.15. Experimental blinding procedures: The experimenter, Greg Corder, was blind to
drug

treatments

during

all

behavioral

pharmacology

experiments.

This

was

accomplished by making each drug and vehicles in similar tubes and to the same
volume. These tubes were then given to Renee Donahue, Jennifer Grasch, Ryan
Griggs, Weisi Fu or Suzanne Doolen for tube coding. Greg was then given the tubes
marked with distinguishing letters. After the experiment, the code was broken and Greg
analyzed the data. For i.c.v. experiments, Dr. Felipe Porto helped with animal handling
and blinding.
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3.3. Rationale and Results

3.3.1. Endogenous opioidergic cellular withdrawal relies on NMDA-R activity
Our lab recently reported that peripheral nerve injury produces a potentiated
increase in glutamate-evoked Ca2+ mobilization in lamina II dorsal horn neurons,
coinciding with the manifestation of neuropathic pain (Doolen et al., 2012). To determine
if spinal glutamatergic sensitization resolves alongside inflammatory pain, Dr. Suzanne
Doolen and I assessed Ca2+ transients in spinal neurons in response to brief (10 s)
exogenous bath-application of glutamate (0.3 mM). Fura-2 ratiometric analysis of lumbar
spinal cord slices revealed that glutamate induced a small rise of intracellular [Ca2+] in
neurons from uninjured naïve mice (Figure 3.1a; 340 nm/380 nm ratio = 0.0221 ±
0.0014). However, the Ca2+response was significantly greater 3d after CFA compared to
sham mice (340 nm/380 nm ratio = 0.0492 ± 0.0062 in CFA vs. 0.0311 ± 0.0027 in
Sham, F3,17 = 15.23, P < 0.0001), consistent with observations 24 hr after CFA (Luo et
al., 2008). The potentiated Ca2+ signals were not observed 21d after CFA (340 nm/380
nm ratio = 0.0254 ± 0.0073 in CFA vs. 0.0303 ± 0.0011 in Sham), matching the temporal
onset and resolution of inflammatory hyperalgesia.
We next tested the hypothesis that similar NMDA-R and Ca2+-dependent
mechanisms which induce central sensitization and long-term potentiation (LTP) during
the induction of inflammatory hyperalgesia (Latremoliere and Woolf, 2009; Luo et al.,
2008) are required for the induction of pain reinstatement. Perfusion of either CTOP or
NTX markedly increased the peak amplitude of the glutamate-evoked [Ca2+]i in CFA-21d
but not sham slices (Figure 3.1b-d; CTOP: Sham, 96.09 ± 3.47 % vs. CFA-21d, 145.3 ±
28.03 %; NTX: Sham, 112 ± 3 % vs. CFA 21d, 157 ± 16 %, all values are relative to predrug control responses; P < 0.05). To determine the contribution of NMDA-R activity to
potentiated [Ca2+]i levels, we delivered MK-801, an activity-dependent NMDA-R blocker.
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MK-801 prevented the NTX-mediated rise in [Ca2+]i (Figure 3.1d; Sham: 107 ± 7 % over
control vs. CFA 21d: 104 ± 5 % over control; F1,16 = 4.6, P < 0.05).
NMDA-R-derived Ca2+ flux is necessary for ERK activation (Krapivinsky et al.,
2003; Lever et al., 2003; Sindreu et al., 2007), specifically under pathological conditions
or noxious stimulation (Ji, 2004; Matsumoto et al., 2008). We found that pre-treatment
with intrathecal MK-801 (3 nmol) resulted in prevention of NTX-induced hyperalgesia
(Figure 3.1g; F3,88 = 5.4, P < 0.005) and loss of bilateral increases in dorsal horn pERK
levels (Figure 4.1e-f, ipsilateral and contralateral; both P < 0.05 compared to Vehicle +
NTX). Together these results reveal that loss of tonic MOR signaling initiates an NMDAR─Ca2+─pERK pathway to generate the reinstatement of pain.
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Figure 3.1. NMDA-receptor-mediated Ca2+ signaling is required for pain
reinstatement and dorsal horn neuron activity during endogenous opioid cellular
withdrawal.
(a) Time course of glutamate-evoked (0.3 mM) intracellular calcium concentrations in
adult spinal cord slices from naïve, sham or CFA mice. (n = 4 – 7). (b) Glutamate-evoked
calcium levels in the presence of vehicle, CTOP (1 µM), NTX (1 µM) or NTX+MK-801
(100 µM). (n = 3-6 mice, 1-2 slices per mouse).  P < 0.05 compared to Sham. (c)
Representative F380 nm image of dorsal horn neurons responding to glutamate
stimulation before (control, top row panels) and 15 min after continuous NTX (10 µM,
bottom row panels) perfusion in a spinal cord slice from a CFA-21d mouse. A decrease
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in fluorescence intensity corresponds to increases in intracellular [Ca2+] since basal
Fura-2 fluorescence is decreased by 380nm light.

The red traces illustrate the Δ

F340/F380 for the glutamate-evoked rise in [Ca2+]i in the indicated cell (red arrow).
Vertical Δ F340/F380 scale = 0.02, horizontal time scale = 3 min; scale bar =100 µm.
Insets at upper left depict area in white box; scale bar = 10 µm. The F380nm, in lieu of
the ratiometric F340/380 image was selected for the sake of clarity. Fura-2 AM is excited
at both 340nm and 380 nm light. The magnitude in fluorescence decrease following
380nm exposure is greater (and therefore easier to see by eye) than the magnitude of
fluorescence intensity following 340nm exposure. Thus, to adequately show a significant
rise in intracellular calcium levels the 380nm is displayed. (d-f) Effect of intrathecal MK801 (1 µg) on NTX-precipitated (d) mechanical hyperalgesia and (e and f) light-touch
evoked pERK in lamina I-Ii or III-IV. (n = 5-10).  P < 0.05 compared to ‘Vehicle +
vehicle’;  P < 0.05 compared to ‘MK-801 + NTX’. Data shown as mean ± s.e.m. Dr.
Suzanne Doolen performed the calcium imagining experiments.
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3.3.2. Endogenous opioidergic withdrawal precipitates an NMDA-R-dependent adenylyl
cyclase superactivation
Opioids produce their acute actions in part through inhibition of adenylyl cyclases
(ACs), whereas chronic opiate exposure produces a homeostatic upregulation of ACs
(Nestler and Aghajanian, 1997; Christie, 2008). In this opioid-dependent state, opioid
receptor antagonists produce cellular withdrawal, characterized by a cAMP overshoot
response. We hypothesized that similar homeostatic mechanisms operate in the setting
of tonic opioid receptor signaling after injury. To address this novel concept, Dr. Brandon
Jutras and Greg Corder sampled intracellular cAMP content from ex vivo lumbar spinal
tissue using an ELISA assay. While basal spinal cAMP levels were comparable in sham
and CFA 21d mice (Figure 3.2a), intrathecal CTOP or NTX dramatically increased cAMP
levels in CFA-21d mice (Figure 3.2a; P < 0.05), indicative of AC superactivation.
Because the Ca2+ stimulated isoforms of ACs are activated by NMDA-Rs (Chetkovich
and Sweatt, 1993) and we have shown that NMDAR signaling is necessary for
hyperalgesia reinstatement, we next hypothesized that NMDA-R signaling contributes to
this cAMP overshoot during opioid receptor blockade. Pretreatment with intrathecal MK801 abolished the NTX-precipitated increases in cAMP (Figure 3.2b; P < 0.05 compared
to NTX group). Moreover, direct activation of spinal NMDARs with intrathecal NMDA (3
pmol) increased spontaneous nocifensive behaviors (Figure 3.2c; P < 0.05) and spinal
cAMP levels (Figure 3.2d; P < 0.05) in CFA mice as compared to shams. Similarly, direct
activation of the spinal AC system with intrathecal forskolin (2.5 μg) produced enhanced
spontaneous nocifensive behaviors (Figure 3.2e; P < 0.05) and intracellular cAMP
(Figure 3.2f; P < 0.05). Thus, injury-induced tonic MOR signaling is accompanied by
latent up-regulation in the spinal cord of NMDA-R and AC functional capacity.
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Figure 3.2. Endogenous opioid withdrawal initiates NMDA-R-dependent AC
superactivation.
(a) Effect of forskolin (i.t.; 1.5 µg) on spontaneous nocifensive behaviors (left) and paw
flinches (right) over 15 min in Sham (n = 6) and CFA (n = 6) mice. P < 0.05 compared
to Sham group. (b) Lumbar spinal cord cAMP levels from the same mice in (a) collected
30 min after i.t. injection. (c) Effect of NMDA (i.t.; 3 pmol) on spontaneous nocifensive
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behaviors (left) and paw flinches (right) over 15 min in Sham (n = 5) and CFA (n = 5)
mice.

 P < 0.05 compared to Sham group. (d) Spinal cAMP levels from the same

mice in panel c.

 P < 0.05 compared to Sham group. (e) Spinal cord cAMP content

measured by ELISA at 30 min after intrathecal vehicle (Sham, n=14; CFA-21d, n=18),
CTOP (100 ng; Sham, n=6; CFA-21d, n=6) or NTX (1 µg; Sham, n=6; CFA-21d, n=10).
 P < 0.05. Mice in control groups (Sham+vehicle and CFA-21d+vehicle) across CTOP
and NTX studies were combined. (f) Effect of MK-801 (3 nmol) pretreatment on NTXmediated cAMP superactivation (n = 5 CFA-21d + saline, n = 4 CFA-21 + MK-801, n = 5
CFA-21d + NTX, n = 5 CFA-21d + MK-801 + NTX).  P < 0.05. Student's t test, twotailed. Data shown as mean ± s.e.m. Greg Corder and Dr. Brandon Jutras worked side
by side to perform the cAMP ELISA studies.
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3.3.3. Adenylyl cyclase type 1 is required for endogenous opioidergic cellular
dependence
Ca2+ sensitive adenylyl cyclase type 1 (AC1) is intricately linked to morphine
dependence in the locus coeruleus (Lane-Ladd et al., 1997; Zachariou et al., 2008;
Mazei-Robison and Nestler, 2012) and the maintenance of chronic pain in the anterior
cingulate cortex (Wei et al., 2002). While in the spinal cord AC1 contributes to activitydependent high-frequency-stimulation-induced LTP (Wang et al., 2011). However, the
regulation and contribution of AC1 to injury-induced plasticity in the spinal cord is less
clear (Zhuo, 2012). Therefore, we tested the hypothesis that spinal AC1 is the specific
isoform responsible for the development of cellular dependence to tonic endogenous
opioidergic signaling. To test this hypothesis we intrathecally administered NB001, a
potent selective inhibitor of AC1 (Wang et al., 2011), prior to NTX. NB001, but not saline,
prevented spinal cAMP overshoot (Figure 3.3e; P < 0.05 compared to NTX group) and
hyperalgesia reinstatement (Figure 3.3d; F1,9 = 6.612, P = 0.03). To further demonstrate
the contribution of AC1 to opioid dependence we utilized AC1 knockout mice. As
reported previously (Wei et al., 2002), baseline mechanical thresholds were similar in
wild-type and AC1 knockout mice (AC1-/-) (Figure 3.3a), indicating AC1 does not
facilitate acute nociception. However, AC1 gene deletion significantly reduced
inflammatory hyperalgesia (Figure 3.3a; 3d vs. baseline: P < 0.05, t test; F1,11 = 31.5, P =
0.0002, 2-way ANOVA, Genotype X Time), despite the presence of an intact
inflammatory response (Figure 3.3c). Importantly, the ability of NTX to reinstate
mechanical hyperalgesia in wild-type mice was lost in AC1-/- mice (Figure 3.3b; F1,7 =
20.30, P = 0.002, 2-way ANOVA Gene x Time). We conclude that long-lasting tonic
MOR signaling generates opposing mechanisms (i.e. NMDA-R-AC1 signaling pathways)
that create a state of opioid cellular dependence in the spinal cord. This is manifested as
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cellular withdrawal (increased cAMP) and increased neuronal excitability to facilitate the
reinstatement of hyperalgesia (Figure 3.4).
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Figure 3.3. Superactivation of spinal AC1 facilitates pain reinstatement and opioid
cellular withdrawal.
(a) Progression of CFA-induced mechanical hyperalgesia in AC1-/- (n = 9) and littermate
AC1+/+ mice (n = 4). (b) Effect of intrathecal NTX (1 μg) in AC1-/- and AC1+/+ mice 21d
after CFA. (c) Progression of CFA-induced paw edema in AC1-/- and AC1+/+ mice. (d,e)
Effect of intrathecal NB001 (1.5 µg) on NTX-precipitated (d) mechanical hyperalgesia
(n=4-7) and (e) spinal cAMP content (n=6-9). P < 0.05. Data shown as mean ± s.e.m.
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Figure 3.4. Cellular signaling pathways underlying endogenous opioid withdrawal.
Left to Right: Spinal cord MOR signaling, through inhibitory Gαi/o proteins, tonically
represses AC1 production of cAMP, thereby reducing nociceptive signal transduction.
Blockade of MOR results in the disinhibition of AC1, allowing for NMDA-R-derived,
Ca2+-mediated activation and downstream increases in neuron excitability, signal
transduction, and consequently, hyperalgesia. Gray text indicates pharmacological
inhibitors that act upon the indicated protein of interest.
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3.3.4. Unmasking psychological and physical dependence to supraspinal endogenous
opioidergic signaling
Opioid receptors are widely distributed throughout

all

axes of the nervous

system (Mansour et al., 1995), including the spinal cord and brain. Chronic exposure of
these receptors to opiate drugs leads to physical dependence, such that abstinence or
decrease in dose produces negative physical and affective symptoms. Experimentally,
injection of an opioid receptor antagonist such as naltrexone precipitates a withdrawal
syndrome in opiate-dependent animals. Manifestations of physical withdrawal in rodents
include: autonomic dysfunction; motor abnormalities such as ptosis, paw flutters, body
shakes, and rearing (Maldonado et al., 1992; Kest et al., 2002b); and hyperalgesia
(Sweitzer et al., 2004; Bie et al., 2005; Vera-Portocarrero et al., 2011). Peripheral tissue
inflammation is associated with increased CNS expression of opioid receptors (Ji et al.,
1995; Goff et al., 1998; Calza et al., 2000; Mousa et al., 2002) and increased release of
opioid peptides in pain-modulatory regions of the brain, thereby leading to intrinsic pain
relief (Fields, 2004; Ossipov et al., 2010). Given that opioid peptides and receptor
expression can remain significantly elevated in the brain for several weeks after severe
peripheral inflammation (Hurley and Hammond, 2001), we hypothesized that tissue
injury induces endogenous opioid dependence in the brain, as well as the spinal cord.

3.3.4.1. Psychological withdrawal
Pain comprises sensory (hyperalgesia) and affective (aversiveness) components;
the latter can be identified by changes in the rewarding property of analgesics and
associated motivational behavior. For example, in a conditioned place preference
paradigm (King et al., 2009; He et al., 2012), the negative reinforcing capacity of
intrathecal lidocaine (motivation to seek pain relief) demonstrates the presence of
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aversive spontaneous pain 1d after CFA (He et al., 2012), in addition to the reflexive
pain measured by traditional von Frey and Hargreaves’s assays.
The following studies were designed by Greg Corder, Bradley Taylor and Zaijie
Wang and were performed by Ying He at the University of Illinois at Chicago. We found
that this inflammatory injury-mediated spontaneous pain was completely absent 21 days
after CFA (Figure 3.5a; ‘CFA-21d+saline’ group). This enabled us to determine whether
NTX-reinstated hyperalgesia is accompanied by symptoms of aversive somatic and
psychological withdrawal as well as spinally-driven spontaneous pain. To test these
hypotheses we assessed the aversion associated with somatic endogenous opioid
withdrawal as well as spontaneous pain mediated by the spinal (not supraspinal)
circuitry. During the one-day conditioning session, sham and CFA mice received ‘i.p.
naloxone + i.t. saline’ paired with a randomly chosen chamber in the morning and, 4 hr
later, ‘i.p. naloxone + i.t. lidocaine’, paired with the other chamber (see Methods, page
71, for rationale on use of naloxone in CPP studies). Chamber preference was tested 20
hr later. We found no chamber preference in sham-injured mice treated with naloxone or
in 21d-CFA mice treated with systemic saline (Figure 3.5a and c ; P > 0.05), confirming
lack of spontaneous pain or on-going aversion. In contrast, CFA-21d but not sham mice
responded to systemic naloxone by spending significantly more time in the chamber
paired with intrathecal lidocaine (538 ±39 s) than with intrathecal saline (Figure 3.5a and
c; 283±28 s; P < 0.001). We can infer two conclusions from this finding: 1. systemic
naloxone increases aversive spontaneous pain in CFA21d-mice only and 2. blocking
neural transmissions in the spinal cord produces pain relief induced by endogenous
opioid withdrawal.
We next tested the hypothesis that opioid withdrawal-induced alterations in
motivational behavior (i.e. drive to seek pain relief after opioid receptor blockade) rely on
spinal AC1 superactivation. To do this we pre-administered intrathecal NB001 prior to
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systemic naloxone during the one-day conditioning phase for intrathecal lidocaine
(Figure 3.c and 3.5d). We found that CFA 21d-mice given only naloxone spent
significantly more time in the intrathecal lidocaine paired chamber (P < 0.05), whereas
mice receiving intrathecal NB001 prior to naloxone did not show a preference for either
paired chamber. This demonstrates that the rewarding aspects of intrathecal lidocaine in
opioid-withdrawing mice are blocked by inhibition of spinal AC1.
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Figure 3.5. Endogenous opioid psychological dependence.
(a,b) Behavioral signs of

psychological withdrawal (aversion associated with

spontaneous pain), reflected by place preference for intrathecal lidocaine upon naloxone
administration. (a) Intragroup chamber analysis for intrathecal saline (5 µl) or lidocaine
(0.04%) in sham and CFA-21d mice treated with intraperitoneal saline or naloxone (3
mg/kg). (b) Intergroup difference score analysis illustrating time spent in intrathecal
lidocaine-paired chambers. (n = 6 per group). (c,d) Effect of AC1 inhibition on naloxoneinduced psychological withdrawal. (c) Intragroup chamber analysis for intrathecal saline
(5 µl) or lidocaine (0.04%) in CFA-21d mice treated with intraperitoneal naloxone (3
mg/kg) or intrathecal NB001 (1.5 µg) + intraperitoneal naloxone.

(d) Intergroup

difference score analysis illustrating time spent in intrathecal lidocaine-paired chambers.
(n= 6 – 12).  P < 0.05. Data shown as mean ± s.e.m. Studies designed by Greg
Corder, Bradley Taylor and Zaijie Wang. Studies performed by Ying He.
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3.3.4.2. Somatic withdrawal
To determine whether cutaneous inflammation induced an endogenous opioid
physical dependence, we subcutaneously administered naltrexone (NTX; 3 mg/kg), a
non-selective opioid receptor antagonist that precipitates withdrawal symptoms in
morphine-dependent mice (Wang et al., 2004). When administered 24hr or 3d after
intraplantar sham or CFA injection, NTX did not produce extensive escape/aversive
behaviors (Figure 3.6a-f). Astonishingly, when administered 21d after CFA, NTX
precipitated pronounced somato-motor behaviors that were analogous with classical
morphine physical withdrawal symptoms (Koob et al., 1992; Kest et al., 2002b).
Symptoms began within 5 min of drug administration and lasted approximately 60 m. As
illustrated in Figure 3.6a-f, NTX but not saline precipitated mechanical hypersensitivity
(F2,154 = 5.4, p < 0.05), jumping (F2,88 = 28, p < 0.0001), rearing (F2,88 = 36, p < 0.0001),
and paw flutters (F2,88 = 70, p < 0.0001).
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Figure 3.6. Endogenous opioid physical dependence.
Incidence of opioid receptor antagonist-induced somatic withdrawal behaviors during a
60 min observation session following subcutaneous injection of saline, NTX (3mg/kg) or
NMB (3mg/kg). (a and b) jumping frequency and total, (c and d) rearing frequency and
total, (e and f) paw flutter frequency and total. 2-way ANOVA for behavioral frequency
plots (a,c,e) and Student’s t Test, two-tailed for cumulative plots (b,d,f).  P < 0.05. Data
are s.e.m.
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Additionally NTX, but not saline, precipitated ptosis, body shakes, teeth
chattering and hyperlocomotion (Figure 3.7a-d; all P < 0.05). No such effects were
produced by naltrexone methobromide (NMB), a peripherally-restricted opioid receptor
antagonist (P > 0.05).
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Figure 3.7. Additional somatic withdrawal behaviors indicative of endogenous
opioid physical dependence.
Incidence of opioid receptor antagonist-induced somatic withdrawal behaviors, in the
same mice from Figure 4.6, during a 60 min observation session following subcutaneous
injection of saline, NTX (3mg/kg) or NMB (3mg/kg): (a) ptosis, (b) teeth chatters, (c)
body shakes, and (d) and locomotor activity.  P < 0.05. Data are s.e.m.
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3.3.6. Endogenous opioidergic dependence intensifies over time
Tissue edema completely subsided within 77 d after CFA (Figure 3.1e).
Therefore, to determine if endogenous opioid physical dependence persists beyond
tissue healing, we gave periodic injections of NTX during the course of recovery. In
mice, jumping is frequently considered a sensitive and reliable index of physical
withdrawal intensity (Way et al., 1969; Saelens et al., 1971; Smits, 1975; Bilsky et al.,
1996; Kest et al., 2001; Wang et al., 2004). One-way ANOVA analysis of NTX-induced
escape jumps at 1d, 3d, 21d, 49d and 77d after CFA revealed a significant effect of Time
(Figure 3.8; F4,29 = 14.37, P < 0.0001), suggesting that the magnitude of the physical
withdrawal intensifies with the duration of tonic opioid receptor signaling. Taken together
these data establish that intensifying opioidergic and compensatory neuroadaptations
create a physical and psychological dependence that outlasts early inflammatory pain
and tissue injury.
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Figure 3.8. Endogenous opioid physical dependence strengthens with time after
injury.
Effect of repeated NTX (3 mg/kg) on the number of precipitated escape jumps over 77
days after CFA. (n = 6-8). Repeated measures one-way ANOVA. test. P<0.05. All data
shown as mean ± s.e.m.
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3.3.7. Endogenous opioidergic dependence within the supraspinal circuitry
Numerous signs of opiate physical withdrawal result from receptor blockade in
the CNS (Hand et al., 1988). Therefore, to investigate the selective activity of
supraspinal MORs we administered NTX, CTOP and β-funaltrexamine (β-FNA) directly
into the brain 21d after CFA (Figure 3.9). As expected, intracerebroventricular NTX
(i.c.v., 1 μg), CTOP (100 and 300 ng), nor β-FNA (1 µg) did not produce signs of
physical withdrawal in sham injured control mice (Figure 3.9a-e). By contrast all three
antagonists but not saline elicited somatic withdrawal behaviors: mechanical
hyperalgesia (Figure 3.9a and b; F3,120 = 5.0, p < 0.0001), jumping (Figure 3.9c; F3,80 =
69, p < 0.0001), rearing (Figure 3.9d; F3,80 = 151, p < 0.0001), and paw flutters (Figure
3.9e; F3,80 = 83, p < 0.0001). Importantly, intrathecal NTX or CTOP only precipitated
hyperalgesia; all other somato-motor behaviors were never observed.
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Figure 3.9. Endogenous opioid physical withdrawal symptoms are precipitated by
µ-opioid receptor blockade in the brain.
(a) Effect of i.c.v. injection of saline or NTX (1 µg) on mechanical thresholds in sham and
CFA-21d mice. (n = 6 per group). P < 0.05 compared to all groups. (b) Effect of i.c.v.
injection of saline, CTOP (100 and 300 ng), or β-FNA (1 µg) on mechanical thresholds in
CFA-21d mice (n = 7 – 14).  P < 0.05 compared to saline. Incidence of antagonistinduced physical withdrawal behaviors. (c) jumping, (d) rearing, and (e) paw flutters.  P
< 0.05 compared to Sham + the respective antagonist.  P < 0.05 compared to CFA21d + saline. All data shown as mean ± s.e.m. Data on effects of NTX were collected by
Greg Corder. Data on effects of CTOP and β-FNA were collected by Julio Morales
Medina. Greg Corder analyzed all data.
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3.3.8. Enhanced antinociception and delayed analgesic tolerance to morphine in the
post-hyperalgesic state
One of the major disadvantages of exogenous opiate drugs as pain killers is that
their analgesic efficacy is subject to tolerance (i.e. over time increasing doses of the drug
are required to maintain analgesia). In Figure 2.2b, we showed that opioid receptor
signaling persists for at least 105 days after CFA, thus providing endogenous analgesia
for months. Interestingly we did not detect any general indications of analgesic tolerance
(i.e. spontaneous return of hypersensitivity). Behavioral tolerance to an endogenous
analgesic system is difficult to test directly due to the fine-tuned temporal control of
receptor expression levels, receptor post-translational modifications, receptor recycling
and desensitization rates, and endogenous agonist release. However, we can use an
indirect measure of endogenous MOR tolerance by testing the cross-tolerance effects of
other µ-agonists. To do this, we tested cross-tolerance between endogenous MOR
activity and morphine-induced MOR activity.
Morphine-induced antinociception was evaluated by measuring response
latencies in the hot-plate test (Figure 3.10). We used a dose of morphine (10 mg/kg body
weight, s.c.) that is known to produce sub-maximal analgesia in mice in order to test the
hypothesis that morphine antinociception might be increased. As illustrated in Figure
3.10a and b, the analgesic effect of morphine was significantly potentiated in CFA-21d
mice compared to sham mice (AUC: P < 0.001). Morphine analgesia was more
efficacious, and lasted longer in CFA-21d mice. Basal responses to the hot plate did not
differ between the groups.
Analgesic tolerance to morphine develops with repeated administration. Mice
were injected daily with morphine, and paw-withdrawal latencies were recorded (Figure
3.10c). Although the sham mice had significantly diminished responsiveness to
morphine by day 3, the CFA-21d mice continued to experience enhanced analgesia for 5
106

days (Figure 3.10 and d: AUC: P < 0.001). The analgesic tolerance, in CFA-21d mice,
appeared by day 10. Together, these data demonstrate enhanced and prolonged acute
analgesic effects of morphine (similar to the enhanced analgesic effects on intrathecal
DAMGO; Fig. 2.3e). They also demonstrate a delay development of tolerance in injured
mice, suggesting that tonic endogenous MOR signaling lessens cross-tolerance.
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Figure 3.10. Enhanced acute morphine antinociception and delayed morphine
tolerance in mice with a history of injury.
(a) Timecourse and (b) Area-under-curve analysis of the acute antinociceptive effects of
subcutaneous morphine (10 mg/kg) in sham and CFA-21d mice placed on a 56C
hotplate. (c) Daily timecourse and (d) Area-under-curve analysis of the antinociceptive
efficacy for once-daily subcutaneous morphine (10 mg/kg) in sham and CFA-21d mice
placed on a 56C hotplate. (e) Daily pre-morphine baseline latencies in sham and CFA21d mice during 10 days of morphine administration. (n = 7 – 8).  P < 0.001. All data
shown as mean ± s.e.m.
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3.4. Discussion
3.4.1. Pain reinstatement is the result of endogenous opioid cellular withdrawal in the
spinal cord
Earlier we showed evidence that NTX disinhibits an underlying nociceptive
sensitization (Chapter 1), arguing that neither opioidergic nor pronociceptive systems
have abated in the post hyperalgesia state. Based on these results we hypothesize that
these long-lasting adaptations serve to stabilize the level of sensory information
transmitted through the central pain circuitry. The parallel upregulation of these opposing
systems represents a new physiological set-point for dynamic excitation/inhibition
balance, adhering to the principles of allostasis (Koob and Le Moal, 2001) (Figure 3.11,
page 112; discussed further in Chapter 5: Final Discussion). During pharmacological
blockade of spinal MOR signaling we found that the pronociceptive processes relied on
NMDA-R signaling for the full expression of pain reinstatement and nociception
transduction (spinal pERK, cAMP and potentiated [Ca2+]i). Indeed, allostasis of
opioidergic and NMDA-R activity has been suggested following environmental stress (Le
Roy et al., 2011) or injury (Rivat et al., 2002; Rivat et al., 2007), as a pathological
consequence of increased endogenous opioid tone. How might long-lasting MOR
signaling

contribute to the persistence of

pathological nociceptive plasticity?

Neuroadaptations result from prolonged exogenous opioid exposure, specifically
compensatory increases in the expression of Ca2+-sensitive AC1 and AC8 (Lane-Ladd et
al., 1997). These augmentations are revealed during opioid withdrawal and produce
cAMP overshoot, leading to excitatory synaptic plasticity via protein kinases and
MAPK/ERK pathways (Christie, 2008). Indeed, Ca2+ influx via NMDA-R is essential for
ERK phosphorylation (Lever et al., 2003;Sindreu et al., 2007). Ca2+ can elevate
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intracellular cAMP levels leading to the activation of PKA. PKA then activates ERK
pathway through Rap1, then B-Raf (Impey et al., 1999).
Consequently we proposed that prolonged endogenous-mediated MOR signaling
drives the upregulation of the adenylyl cyclase system.

We found that intrathecal

forskolin or N-methyl-D-aspartic acid both produced enhanced pain behaviors and cAMP
levels in CFA mice (Figure 3.2), indicating that Ca2+-sensitive AC expression is
increased. MOR blockade disinhibited spinal ACs leading to cAMP overshoot that was
abolished by MK-801 and NB001. Together our data suggest that a population of spinal
neurons is physically dependent on endogenous opioidergic activity to prevent the
expression of pronociceptive NMDA-R–AC1 neuroadaptations (Figure 3.11 and Figure
3.4).
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Figure 3.11. Allostatic load between tonic µ-opioid receptor activity and opponent
excitatory processes increase the potential for chronic pain.
Under naïve conditions nociceptive and opioidergic systems have little to no activity,
resting at a basal set point (homeostasis). Following injury or strong nociceptive input
the pro-nociceptive systems are sensitized to facilitate the experience of pain
(nociceptive sensitization). In order to reduce rampant nociception and pain counteradaptive, endogenous inhibitory systems are enhanced (opioidergic counter-adaptation).
A state of allostasis is generated once a new equilibrium or set point between pronociceptive and endogenous analgesic processes is reached. The intensity and degree
of sensory information transmitted through the nociceptive system returns to pre-injury
levels (i.e. pain has resolved) while the opponent processes are potentiated but
functionally cancel out one another; thus the nociceptive system is dependent on the
counterbalancing signaling of tonic MOR (allostasis). The allostatic state is only
detectable when one of the potentiated systems is removed leaving the other potentiated
system unchecked. Blockade of tonic MOR signaling produces a superactivation of the
NMDA-R─AC1 pathways and subsequent re-emergence of pain (pharmacological
reinstatement).
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3.4.2. Adenylyl cyclase type 1 facilitates endogenous opioid dependence
We found that AC1 gene deletion resulted in reduced acute inflammatory pain
and total loss of NTX pain reinstatement, demonstrating that lack of AC1 upregulation
eliminates the endogenous opioid withdrawal symptoms. However, taken together these
results suggest that tonic MOR signaling, simultaneously, represses AC1 activity and
perpetuates its upregulation, similar to mechanisms observed during opiatedependence.
Furthermore, in our studies, pharmacological inhibition of AC1, with NB001,
prevented the NTX-induced pain reinstatement and cAMP overshoot response,
displaying the selectivity of AC1 to mediate endogenous opioid withdrawal. AC1 is
necessary for the development of chronic pain (Wei et al., 2002) and the expression of
LTP (Xu et al., 2008).

Withdrawal from exogenous opioids results in NMDA-R-

dependent LTP (Drdla et al., 2009). Possibly explaining the hyperalgesia associated with
physical withdrawal. Thus the increased functional activity of NMDA-R and AC1 during
MOR withdrawal suggests that loss of opioidergic signaling results in spinal LTP.
NTX-induced pain reinstatement (e.g. abrupt withdrawal from tonic MOR
signaling) could result from either: 1) disinhibition of tonically active primary afferent
terminals: 2) disinhibition of AC1 superactivation in dorsal horn neurons; 3) potentiation
of descending facilitatory signals from the brainstem; and/or 4) induction of de novo
spinal NMDA-R-dependent withdrawal. While we have no direct evidence of withdrawalinduced de novo LTP, several of our data and other studies suggest this as a promising
area of future investigation:
1) Exogenous opiate withdrawal in the spinal cord initiates de novo NMDA-Rdependent LTP (Drdla et al., 2009; Zhuo, 2010);
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2) NMDA-R signaling and post-synaptic spinal neuron Ca2+ rise are required in
the induction, rather than maintenance, of spinal LTP and hyperalgesia
(Weyerbacher et al. 2010; Sandkuhler, 2012);
3) AC1 is activated by NMDA-R-derived Ca2+ and is necessary for LTP induction
(Wang et al., 2011; Liauw et al., 2005; Wei et al., 2006);
4) Intrathecal NMDA (3 pmol) increased pain behaviors and spinal cAMP levels
in CFA-21d mice compared to shams (Figure 3.2). This suggests that spinal
NMDA-R–adenylyl cyclase signaling pathways are not occluded (saturated); and
5) Intrathecal MK-801 alone did not increase mechanical threshold (Figure 3.1),
decrease basal pERK expression (Figure 3.1), or decrease basal cAMP levels
(Figure 3.2) when administered during the post-hyperalgesia state. In addition,
MK-801 perfusion did not reduce basal spinal intracellular calcium levels from
CFA-21d slices (Figure 3.2). Together, these findings suggest that spinal NMDARs are not active prior to NTX-induced withdrawal.
We propose that the incidence of long-lasting, tonic MOR signaling within the
spinal nociceptive system promotes a physical and cellular dependence on tonic MOR
signaling. Therefore, it stands to reason that withdrawal from MOR would result in
spontaneous activation of those dependent-cells (possibly NK1R positive projection
neurons or PKCγ excitatory interneurons in lamina I and II), through de novo generation
of LTP, leading to subsequent reinstatement of pain (see Figure 5.2 for a schematic
representation of potential intracellular signaling cascades that would facilitate
endogenous opioidergic withdrawal-LTP).
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3.4.3. Endogenous opioid dependence occurs in supraspinal circuitry
Humans and other mammals develop tolerance and physical dependence to
exogenous opiate drugs. By contrast, endogenously-released peptides are not generally
thought to produce tolerance or physical dependence. Therefore, we found it remarkable
to observe that, when administered 21 days after the induction of inflammation, NTX
produced robust behaviors (jumping, paw flutters, rearing, ptosis, teeth chattering, body
shakes, hyperlocomotion, and mechanical hypersensitivity) identical to withdrawal from
exogenous opiates. This is the first set of experiments to describe a physical
dependence to endogenous opioid activity in the setting of persistent inflammation.
3.4.3.1. Endogenous opioidergic dependence occurs during other forms of
chronic physiologic stress.
We found that NTX did not change sensory thresholds and did not produce
aversive behaviors in sham-injured mice. This is consistent with other studies using
opioid receptor antagonists in opiate-naïve or uninjured rodents and humans (El-Sobky
et al., 1976; Wang et al., 2001; Wang et al., 2004; Schoell et al., 2010). These data
indicate that endogenous opioid dependence is causally initiated by the cutaneous
inflammatory insult. However, many chronic pain models are also accompanied by signs
of increased HPA-axis activity and stress, such as increased circulating glucocorticoids
and pro-inflammatory cytokines, which could initiate opioid receptor signaling in brain
regions not directly activated by ascending nociceptive signals. In fact other
environmental or dietary factors have been previously suggested to induce CNS
manifestations of endogenous dependence. The first account was described in rats
repeatedly stressed for 10 days and then given naloxone, which produced “wet-dog”
(body) shakes indistinguishable from opiate withdrawal (Morley and Levine, 1980).
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Second, naloxone precipitated piloerection, ptosis, and body shakes following a stressful
chronic schedule of warm water swimming (Christie and Chesher, 1982).

Third,

naloxone produced very mild symptoms of forepaw tremor and decreased body weight
following the chronic delivery of RB101, an enkephalinase inhibitor (Noble et al., 1994).
Fourth, naloxone precipitated somatic indices of withdrawal (teeth chattering, forepaw
flutters, and head shaking) and anxiety (reduced time on the exposed arm of an elevated
plus maze), as well as a dopamine/acetylcholine imbalance in the nucleus accumbens,
following excessive ingestion of sugar (Colantuoni et al., 2002). Therefore, it is difficult
to distinguish whether the initiation of opioid physical dependence in the brain is a direct
result of inflammatory injury/nociception or that of an elevated stress response.
3.4.3.2

Possible

cellular

mechanisms

driving

endogenous

opioidergic

dependence.
We found that endogenous opioid dependence persists after the cutaneous
edema has subsided (Figure 3.8). We propose that endogenous opioid dependence
develops and strengthens gradually over time following the induction of inflammation but
that dependence is not maintained by injury. We propose two mechanisms to explain the
long-lasting nature of endogenous opioid dependence. First, inflammation causes the
release of enkephalins and dynorphins in several brain areas including the RVM (Hurley
and Hammond, 2000, 2001; Schepers et al., 2008a), locus coeruleus, arcuate nucleus
and periaqueductal gray (Porro et al., 1991; Zangen et al., 1998) to provide intrinsic pain
relief (Fields, 2004; Ossipov et al., 2010). Because these brain regions are also
implicated in the expression of somatic withdrawal during opiate dependence
(Maldonado et al., 1992; Vera-Portocarrero et al., 2011), we speculate that blockade of
this ligand-dependent opioid receptor signaling with NTX reverses the actions of
endogenous opioids, leading to physical withdrawal. Second, inflammation might
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sensitize opioid receptors such that receptor signaling continues in the absence of
peptide binding and ligand activation. As suggested by dependence studies using
exogenous opiate drugs, continual receptor stimulation might transform the opioid
receptor into a constitutively active state (Liu and Prather, 2002; Wang et al., 2004). We
speculate that injury-induced release of endogenous opioid peptides, released
throughout the 21-day recovery time course in our studies, may have a similar effect on
intrinsic signaling. If true, then NTX would act as an inverse agonist to decrease basal
signaling (see Chapter 4 for studies investigating constitutive activity of spinal opioid
receptors).
3.4.3.3. Possible supraspinal structures involved in endogenous opioidergic
dependence.
Brainstem areas thought to mediate endogenous opioid dependence in the
setting of stress or high sugar diet include mesolimbic reward circuits. Other candidates
include CNS noradrenergic systems such as the locus coeruleus. The locus coeruleus
contributes to the locomoter hyperactivity associated with opiate withdrawal, such as
jumping, rearing and forepaw flutters, (Aghajanian, 1978; Llorens et al., 1978; Koob et
al., 1984; Maldonado et al., 1992). Of particular interest is the rostral ventral medulla
(RVM), identified as a key regulator of chronic inflammatory nociception (Hurley and
Hammond, 2001; Finnegan et al., 2004; Zhang and Hammond, 2010) and mediator in
the manifestation of opiate withdrawal (Vera-Portocarrero et al., 2011). In opiatedependent animals, lidocaine inactivation of the RVM diminished naloxone-precipitated
hyperalgesia and other aversive withdrawal symptoms such as teeth chattering, body
shakes, and writhing. Further studies are required to pinpoint critical cerebral structures
involved in the endogenous opioid physical dependence associated with tissue
inflammation.
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3.4.3.4. Intensity of opioid somatic withdrawal may depend on route of
administration
Compared to subcutaneous administration, we found that i.c.v. NTX produced
less jumping, paw flutters, teeth chattering and body shakes. One explanation is that
only after systemic administration can sufficient concentrations of NTX reach critical
hindbrain structures. Consistent with this idea, more intense withdrawal is produced
following injection of naloxone into the fourth ventricle as compared to the third ventricle
(Herz et al., 1972; Laschka et al., 1976). This may also explain why intrathecal NTX
does not produce overt jumping, paw flutters, body shakes behaviors, etc. (anecdotal
observations).
3.4.4. Delayed morphine analgesic tolerance in injured mice
In Figure 3.10, we demonstrated that the occurrence of analgesic tolerance to
morphine is delayed in mice with a prior CFA-injury. Unlike tolerance to exogenous
opioids, endogenous opioid mechanisms do not readily undergo antinociceptive
tolerance. For example, enkephalinase inhibitor drugs (i.e. RB101), which prevent
degradation of released enkephalin opioid peptides, produce analgesia that does not
undergo tolerance or cross-tolerance to morphine (Noble et al., 1992). Furthermore, the
presence of tissue inflammation reduces peripheral morphine tolerance. This relied on
injury-induced increased opioid peptide stimulation of MORs in the dorsal root ganglia,
increased MOR endocytosis, intact G-protein coupling and cAMP inhibition (Zollner et
al., 2008). These studies suggest that opioid peptides and exogenous opiate drugs
differentially regulate MOR desensitization and internalization mechanisms. In fact,
Robert Lefkowitz and Marc Caron’s groups found increased morphine antinociception
(Bohn et al. Science 1999) and decreased tolerance (Bohn et al. Nature 2000) in βarrestin2 KO mice (a regulatory protein responsible for MOR internalization). Importantly,
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their findings were later found to rely on MOR constitutive activity (Lam et al. Mol Pain
2011), which will be further discussed in Chapter 4: µ-Opioid receptors display in vivo
constitutive activity after injury.
3.4.5. Future Studies
1. NTX-induced pain reinstatement (e.g. abrupt withdrawal from tonic MOR
signaling) could result from either: 1) disinhibition of tonically active primary afferent
terminals: 2) disinhibition of AC1 superactivation and/or tonically active NMDA-Rs in
dorsal horn neurons; 3) potentiation of descending facilitatory signals from the
brainstem; and/or 4) induction of de novo spinal NMDA-R-dependent withdrawal. While
we have no direct evidence of withdrawal-induced de novo LTP, several of our data and
other studies suggest this as a promising area of future investigation. This evidence is
discussed in section 3.4.2 above.
Altogether our evidence suggests that spinal NMDA-Rs are not active prior to
NTX-induced withdrawal. Therefore, we propose that the incidence of long-lasting, tonic
MOR signaling within the spinal nociceptive system promotes a physical and cellular
dependence on tonic MOR signaling. This mechanism would also imply that withdrawal
from MOR would result in spontaneous activation of those dependent-cells (possibly
NK1R positive projection neurons or PKCγ excitatory interneurons in lamina I and II),
through de novo generation of LTP, leading to subsequent reinstatement of pain (Figure
5.2).
In a collaborative pilot study with Dr. Min Zhuo (University of Toronto), using a
multi-electrode array recording technique that stimulates and records field potentials
across 64 channels overlaying a dorsal horn slice, NTX (1 μM) increased excitatory
synaptic responsiveness in these spinal cord circuits. These findings of enhanced
synaptic signaling may share common mechanisms with spinal LTP induced by electrical
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stimulation. Future studies should use electrophysiological techniques, such as patchclamp recording of spinal neurons or in vivo field potential recordings using tetanic
stimulation of dorsal roots, to test the hypothesis that NTX induces LTP.

2. As illustrated in Figure 3.9, i.c.v. NTX, CTOP and β-funaltrexamine reinstate
hyperalgesia in the hindpaw. This suggests that descending facilitation is disinhibited by
the opioid receptor antagonists. In certain injury states, the RVM maintains spinal
sensitization (Fields, 2004; Vanegas et al., 2004; Ossipov et al., 2010; Urban et al.,
1999; Mansikka et al., 1997). MOR agonists into the RVM produce their antinociceptive
effects through opening of Kir channels to hyperpolarize “on-cells” (Pan et al., 1990;
Heinricher et al., 1992; Chieng et al., 1994) and disinhibiton of GABAergic “off-cells”
(Heinricher et al., 1992; Heinricher et al., 1994). If “on-cell”- MORs tonically inhibit RVMpain-facilitation, then CTOP into the RVM may reinstate hypersensitivity. The δOR
antagonist naltriben in the RVM of CFA-treated rats enhanced hindpaw hyperalgesia
(Hurley et al., 2001). Increased levels of met- and leu-enkephalin in the RVM were also
noted 2 weeks post-CFA. Therefore, MOR and/or δOR blockade, within the RVM, may
also reinstate hindpaw hyperalgesia in our model. Additionally, future studies could
replicate the use of cAMP ELISAs, NB001, ex vivo Ca2+ imagining, and GTPγS35 binding
experiments on RVM tissue to determine if the cellular opioid receptor, AC1 and NMDAR mechanisms, in the spinal cord, exist in the brainstem or other nuclei within the CNS
nociceptive circuitry (see Figure 2.2 schematic circuitry diagram of CNS pain pathways).

Copyright © Gregory F. Corder 2013
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CHAPTER 4

µ-Opioid receptors display in vivo constitutive activity after injury

4.1. Introduction
G-Protein-Coupled-Receptors (GPCRs), also known as 7-Transmembrane
Receptors (7TMRs), represent the largest class of receptor drug targets for clinical
pathologies. All three opioid receptors, µ-, δ- and κ-, belong to the rhodopsin family
(Class A) of 7TMRs and have been extensively investigated as potential therapeutic
targets for disorders ranging from depression to severe pain (Lutz and Kieffer, 2013).
For example, morphine, a ligand for the µ-opioid receptor (MOR), reduces pain by
binding to the extracellular binding domain of MORs which causes a conformational
change in the receptor which allows for G-protein binding and intracellular signal
transduction. Thus the positive efficacy of morphine broadly classifies this drug ligand as
an agonist. This simple two-state model expounds that the receptor rests in an inactive
conformation (Ri) and with the addition of an agonist (A), the receptor becomes active
(Ra) and subsequently binds to a G-protein (ARaG) (Figure 4.1a).
The actions of agonists can be blocked by addition of antagonists which prevent
binding of the agonist to the receptor. This can occur through competition for the binding
pocket or at an allosteric site. Regardless of mechanism, the definition of a true
antagonist describes its action in terms of blocking an agonist without effecting receptor
conformations that might alter signaling (i.e. antagonists do not have efficacy at a given
receptor for either the active or inactive state) (Figure 4.1b).
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Figure 4.1. Modeling GPCR constitutive activity.
(a) The Extended Ternary Complex model of GPCR signaling which predicts that
modulating the allosteric constant (red arrows) produces a spontaneously active
receptor (Ra). Ra can then bind to G-proteins (G) independent of agonist (A) facilitation
(pink arrows). (b) Effect of various ligands on 7TMR/GPCR activity.
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It was assumed that most GPCR drugs were either agonists or antagonists
acting on basally inert GPCRs until it was experimentally demonstrated by Costa and
Herz (1989) that overexpression of recombinant delta opioid receptors in NG-108-15
neuroblastoma cells could assume an active signaling state in the absence of a ligand.
Some antagonists were able to reduce basal GTPase activity of pertussis toxin sensitive
G-proteins, while other antagonists did not. Thus the term inverse agonist was used to
describe ligands that display negative efficacy (Figure 4.1b). Negative efficacy is the
idea that an antagonist binding to its receptor can be ‘active’ in repressing the
spontaneous activity of the receptor. In fact, in 1980 De Lean et al. had postulated the
theoretical existence of agonist-independent GPCR activity in their Ternary Complex
model (De Lean et al., 1980), which was later expanded to the Extended Ternary
Complex (ETC) model (Costa and Cotecchia, 2005) (Figure 4.1a). Based on the
thermodynamics of the fluid biophysical nature of the seven transmembranes of GPCRs
within a lipid bilayer, it was predicted that GPCRs exist in equilibrium of spontaneous Ra
and Ri states, known as an allosteric constant. This constant represents the unique
energy barrier for a given GPCR in a specific cellular environment which dictates the
formation of spontaneous Ra states. Thus, lowering the allosteric constant (e.g. receptor
point mutations, removal of Na+ ions, loss of negative regulatory/internalizing/
desensitizing proteins) increases the formation of Ra.
In the past few decades most GPCRs have been shown to display constitutive
activity, including MORs. However the physiologic influence of constitutive signaling has
not been fully explored. Constitutively active α1B-adreno-receptors enhance the
transforming potential of quiescent fibroblasts, suggesting that mutations in GPCRs may
be a possible cause of disease. In fact, mutations in several GPCRs causing constitutive
activity have been linked to ovarian cancer (Zeineldin et al., 2010) and other human
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diseases, such as hyperthyroidism and precocious puberty (Shenker et al., 1993;
Mueller et al., 2010).
To date, approximately 30 different studies using site-directed point-mutations in
the oprm1 gene encoding MOR have found numerous amino acids that affect ligand
binding, G-protein coupling efficiency, and receptor phosphorylation and internalization;
all of which increase constitutive activity of MORs (MORCA). Importantly, genetic
mutations are not necessary for constitutive activity to occur. Liu and Prather
demonstrated that prolonged exposure of morphine can induce constitutive activity that
persists after agonist washout (Liu and Prather, 2001), suggesting that post-translational
modifications to MOR or decreased interactions with negative regulatory proteins may
induce constitutive activity. In whole animal studies, MORCA is detectable in the
brainstem of morphine dependent mice, which is hypothesized to preserve opioid
dependence and addiction (Wang et al., 2004; Shoblock and Maidment, 2006). Whether
MORCA is important in disease states other than drug addiction, such as chronic pain, is
unclear. What would be the potential physiological benefits and drawbacks of acquiring
tonic MORCA after suffering an injury?
In previous chapters we have demonstrated that spinal MORs become tonically
active after injury and continue to signal beyond wound healing; the consequence of
which appears to be endogenous opioid dependence. Here we investigate potential
receptor mechanisms by which MORs remain active for such long periods of time.

125

4.2. Methods and Materials
4.2.1. Mice:

For species, sex, and age, please refer to section 2.2.1, page 27.
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Table 4.1. Animal use quantification for figure 4.2.
Figure

4.2a

4.2b

4.2c

4.2f,g

Group n at
start of
experiment

Group n
reported in
analysis and
figures

Comments on mouse
removal

Year of
experiment

Sham+CTOP: 4
Sham+NTX: 4
Sham+6Bnaltrexol: 5
Sham+6Bnaltrexol+NTX: 6
CFA+CTOP: 5
CFA+NTX: 5
CFA+6Bnaltrexol: 5
CFA+6Bnaltrexol+NTX: 6
Exp. 1:
Sham+vehicle: 5
Sham+NTX: 5
CFA+vehicle: 10
CFA+NTX: 10

Sham+CTOP: 4
Sham+NTX: 4
Sham+6Bnaltrexol: 5
Sham+6Bnaltrexol+NTX: 6
CFA+CTOP: 5
CFA+NTX: 5
CFA+6B-naltrexol:
5
CFA+6Bnaltrexol+NTX: 6
Sham+vehicle: 7
Sham+NTX: 6
CFA+vehicle: 11
CFA+NTX: 15
Sham+6Bnaltrexol: 5
CFA+6B-naltrexol:
5
Sham+6Bnaltrexol+NTX: 5
CFA+6Bnaltrexol+NTX: 5

n/a

2012

Exp. 1 and 2 were combined.

2012

Sham+vehicle: 6
Sham+NTX: 6
Sham+6Bnaltrexol: 7
Sham+6Bnaltrexol+NTX: 7
CFA+vehicle: 6
CFA+NTX: 6
Sham+6Bnaltrexol: 7
CFA+6BCFA+NTX: 7
Sham: 9
CFA: 7

n/a

2012

Spinal cords were damaged during
dissection

2011

Exp. 2:
Sham+vehicle: 2
Sham+NTX: 1
CFA+vehicle: 1
CFA+NTX: 5
Sham+6Bnaltrexol: 5
CFA+6Bnaltrexol: 5
Sham+6Bnaltrexol+NTX: 5
CFA+6Bnaltrexol+NTX: 5
Sham+vehicle: 6
Sham+NTX: 6
Sham+6Bnaltrexol: 7
Sham+6Bnaltrexol+NTX: 7
CFA+vehicle: 6
CFA+NTX: 6
Sham+6Bnaltrexol: 7
CFA+6BCFA+NTX: 7
Sham: 10
CFA: 10

Unknown information is denoted by dashed lines (--).
Information that is not applicable is denoted as n/a
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4.2.2. Complete Freund’s Adjuvant (CFA) model of inflammatory pain:

Please refer to

section 2.2.2, page 30.
4.2.3. Mouse (in vivo) drug administration:
4.2.4. Drug dosing:

Please refer to section 2.2.5, page 31.

4.2.5. Mechanical hyperalgesia testing:
4.2.6. cAMP ELISA assay:

4.2.8. Calcium Imaging:

Please refer to section 2.2.6, page 32.

Please refer to section 3.2.11, page 78.

4.2.7. GTPγS35 binding assay:

4.2.9. Statistics:

Please refer to section 2.2.4, page 30.

Please refer to section 2.2.12, page 35.

Please refer to section 3.2.13, page 78.

Please refer to section 2.2.13, page 36.

4.2.10. Experimental blinding procedures: Please refer to section 2.2.14, page 37.

4.3. Results
4.3.1. MOR inverse agonists, but not neutral antagonists, block constitutive
receptor signaling in vivo.
Tonic GPCR signaling arises from either continuous agonist binding to and/or
constitutive activity (spontaneous signal transduction that occurs in the absence of
agonist stimulation) of MOR (Costa and Herz, 1989; Kenakin, 2001; Seifert and WenzelSeifert, 2002; Kenakin, 2004). MOR constitutive activity (MORCA) is typically studied
using in vitro systems. Important clues come from a few in vivo studies suggesting that
MORCA develops with chronic morphine administration, leading to physical and affective
signs of opiate dependence and addiction (Wang et al., 1994; Wang et al., 2004;
Shoblock and Maidment, 2006, 2007; Meye et al., 2012). Although β-arrestin2 deletion
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mutant mice exhibit elevated MORCA that is linked to a decrease in transient heat pain
(Lam et al., 2011), the existence and physiologic significance of MORCA in pathological
pain processing is unknown. To address this question we used the neutral antagonist
6β-naltrexol (10 μg in 5 μl 1% DMSO), a structural analog of NTX (Raehal et al., 2005).
Neutral antagonists have little or no intrinsic effect on receptor activity themselves, and
competitively block not only the effects of agonists, but importantly, the effects of inverse
agonists as well (Wang et al., 1994; Bilsky et al., 1996; Raehal et al., 2005; Sally et al.,
2010). Accordingly, we found that intrathecal 6β-naltrexol alone did not change Ca2+
levels in sham or CFA-21d spinal slices (Figure 4.2a), and failed to precipitate a cAMP
overshoot (Figure 5.2b) or hyperalgesia (Figure 4.2c). 6β-naltrexol abolished the ability
of NTX to produce Ca2+ mobilization (Figure 4.2a; P < 0.05), cAMP overshoot (Figure
4.2b; P < 0.05) and hyperalgesia (Figure 4.2c; P < 0.05). These data are consistent with
the assumption that NTX behaves as an inverse agonist to inactivate basal signal
transduction (Sadee et al., 2005; Lam et al., 2011).
4.3.2. β-funaltrexamine blocks MOR constitutive activity in vivo and reduces
basal G-protein coupling.
Intrathecal administration of an alternative µ-selective inverse agonist, βfunaltrexamine (β-FNA; 2.5 μg in 5 μl water) (Liu et al., 2001), reinstated hyperalgesia in
injured but not sham mice (Figure 4.2d; P < 0.05). Since MORCA results in elevated
basal G-protein cycling (Liu et al., 2001; Wang et al., 2004), we determined whether βFNA could promote the MOR-inactive state and thereby decrease spontaneous basal
GDP/GTPγS35 exchange. In CFA-21d spinal cord slices, β-FNA concentrationdependently reduced basal GTPγS35 binding in ipsilateral (Figure 4.2e and f; Emin of 30.94 ± 0.74% and an EC50 of 0.55 ± 0.05 µM) and contralateral dorsal horn (Figure
4.2g; Emin of -18.89 ± 1.19% and an EC50 of 0.3 ± 0.07 µM). β-FNA also decreased basal
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binding in sham-injured slices, but to a significantly lesser degree (Figure 4.2e-g;
Ipsilateral: Emin: -15.44 ± 0.31%; EC50: 0.23 ± 0.04 µM; Contralateral: Emin: -14.51 ±
1.57%; EC50: 0.38 ± 0.11 µM). These data establish that inflammation causes a
population of spinal MORs to adopt a constitutively active state that allows for tonic
intracellular G-protein signaling that is independent of ligand activation.
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Figure 4.2. Spinal µ-opioid receptors acquire constitutive activity after injury.
(a,b,c) Effects of NTX (10µM or 1 µg), 6β-naltrexol (1µM or 10 µg) or co-administration
of 6β-naltrexol+NTX in sham and CFA-21d mice on (a) intracellular calcium
concentration in spinal cord slices (n = 5 - 6), (b) spinal cAMP content (n = 5 - 15) and
(c) hyperalgesia (n = 6 - 7). (d) Effect of intrathecal β-funaltrexamine (β-FNA; 2.5 µg) on
hyperalgesia in sham and CFA-21d mice (n = 6 - 7). (e) Representative pseudo-colored
radiograms and dose-response effects of β-FNA on basal GTPγS35 binding in lumbar (f)
ipsilateral and (g) contralateral dorsal horns of Sham or CFA-21d mice; inset: group
binding Emax (n = 7 - 9). P<0.05. All data shown as mean ± s.e.m.
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4.4. Discussion
4.4.1. Injury increases the proportion of spinal MORs that display constitutive activity.
Here we have demonstrated, for the first time, in vivo acquisition of constitutive
MOR signaling that naturally develops after injury, without chronic drug dosing (Sadee et
al., 2005) or genetic manipulations (Chavkin et al., 2001). NTX, CTOP and β-FNA had
no effect on pain thresholds in uninjured mice but all produced significant pain
reinstatement in mice with a history of prior injury. This result was recapitulated as
enhanced Ca2+ signaling and cAMP superactivation after inverse agonist treatment, all
from ex vivo spinal tissue of CFA-mice. One major limitation in the interpretation of our
results is that all of our opioid receptor inverse agonists (NTX, CTOP, and β-FNA) do not
reduce constitutive activity, but block the actions of opioid peptide agonists. First, opioid
peptides that are continually released in vivo or in the ex vivo spinal cord slices, or,
second, the trace presence of endogenous agonists that are either not sufficiently
removed during our spinal cord slice washing protocols may give rise to apparent
constitutive activity. However, the lack of effect of 6β-naltrexol, and blockade of NTX
inverse effects by 6β-naltrexol, in all our behavioral and molecular assays, clearly argues
that agonist-independent signaling is present in a population of spinal MORs. In strong
support we demonstrated that β-FNA knocked down the basal GTPγS35 binding levels in
the spinal cord. Interestingly we did observe a small degree of GTPγS35 knockdown in
sham mice, which argues for the presence of constitutive MORs under normal
physiological conditions (Wang et al., 2004; Meye et al., 2012); although inverse
agonists did not produce hypersensitivity on their own.
The chronic administration of opioid agonists, such as morphine or DAMGO,
have been shown to cause an increase in the number of constitutively active opioid
receptors (increased basal GTPγS35 binding, increased Bmax of the agonist-responsive
high-affinity

GTPγS35

binding

site

and
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suppressed

forskolin-stimulated

cAMP

accumulation) during the period of opioid dependence (Wang et al., 2001; Sade´e et al.,
2005; Walker and Sterious, 2005; Xu et a., 2007; Sally et al., 2010). Many opioid
antagonists have been demonstrated to be inverse agonists in times of opioid tolerance
and dependence and are quite effective at precipitating withdrawal to differing degrees
(Wang et al., 2007; SirohWe et al., 2007; Sally et al., 2010). These in vitro studies used
exogenous opioid agonists in an attempt to model opiate analgesic use that leads to
development of tolerance and dependence. While constitutive activity is usually difficult
to detect outside of in vitro heterologous cell expression systems, as described above
(Costa and Herz, 1989; Liu et al., 2001) (Wang et al., 2007), basal MOR signaling was
discovered in the striatum (Wang et al., 2004), and recently the Ventral Tegmental Area
(Meye et al., 2012) of morphine-dependent mice. Inverse agonists decreased basal
GTPγS35 binding, produced cAMP superactivation and disinhibited GABAergic signaling,
indicative of acquired state-dependent activity following chronic receptor stimulation.
Additionally, naloxone has been shown to induce excitatory post-synaptic responses in
frontal cortex and striatal single neurons representing withdrawal to a presumed latent
hyperexcitability of post-synaptic membrane in opiate tolerant rats (Fry, Herz and
Zieglgansberger, 1980). In light of this literature, our data further describe a mechanism
whereby loss of MORCA signaling, in a cellular dependent-state, can spontaneously
cause neuronal depolarization. Depolarization of neurons within the nociceptive circuitry
could lead to the propagation of ascending excitatory signals to facilitate spontaneous
pain transmissions.

4.4.2. Mechanisms promoting MOR constitutive activity
As MOR signaling persists for several months after minor tissue damage this
raised questions as to what mechanisms might maintain tonic signal transduction.
Receptor signaling is initiated by either ligand binding or spontaneous acquisition of the
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active conformation. The former scenario is susceptible to antagonists that outcompete
for the receptor binding pocket, while the latter case is blocked by inverse agonists with
preferential affinity for the inactive state of the receptor and, therefore, reverse basal
responses attributed to constitutive activity (Kenakin, 2007) . The concept of constitutive
activity has yet to be fully understood but some postulate that in the presence of
increased exposure to agonists a structural modification, perhaps in the carboxyl tail or
an intracellular loop, leads to either increased G-protein coupling and/or prevents
receptor internalization/desensitization by blocking CaMKII association. Additionally,
constitutive activity can be produced by lowering the energy barrier to spontaneously
form the active state (i.e. decreasing the allosteric constant). This could be achieved
through possible post-translation modification of the receptor (e.g. hyper-phosphorylation
(Wang et al., 1994) or reduction in the association with a negative regulatory protein,
such as β-arrestin2 (Lam et al., 2011). It remains an interesting question as to what
mechanisms underlie constitutive signaling during our in vivo model and warrants further
investigation in the future.

4.4.3. Future Studies
1. We have demonstrated that the basal MORs signaling is increased and is
reduced by NTX, indicating intrinsic constitutive activity of the receptor. However, we
have not definitively ruled out possible parallel receptor signaling mechanisms that
involve opioid peptide-mediated signaling. I propose that future studies could test the
hypothesis that opioid peptides are not being continually released in the spinal cord to
mediate the prolonged endogenous antinociception by intrathecal injection of
sequestering antibodies specific for opioid peptides (leu- and met- enkephalin).
If opioid receptors exclusively signal via constitutively active conformations then
the prediction is that intrathecal enkephalin antibodies will not reinstate pain
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hypersensitivity. However, if hyperalgesia is observed then that would suggest that
opioid peptides are still actively being released in the spinal cord. Alternatively, mRNA
and peptide levels of dynorphin (Chavkin et al., 1982) are markedly increased in the
ipsilateral dorsal horn during peripheral inflammation (Iadarola et al., 1988; Parra et al.,
2002). Spinal dynorphin, however, is reported to be pro-nociceptive by interaction with
bradykinin-R (Lai et al., 2006) and NMDA-R (Tan-No et al., 2002) during chronic
sensitization states (Wang et al., 2001; Gardell et al., 2004). Therefore antiserum for
dynorphin may be analgesic or have no observable effect. An additional experiment
using microdialysis or a push-pull perfusion method for peptide sampling can be
employed to measure active peptide release (Lisi et al., 2006).
Careful attention must be taken to avoid type II negative data and
misinterpretation due to a false positive result. This could arise due to non-specificity of
the antisera or the inability of the antisera to fully sequester the released opioids.
Therefore as a control for antibody binding the antisera (i.t.) should be injected prior to
formalin injection into the paw. It has already been demonstrated that i.t. leu and met
enkephalin antibodies potentiate the 2nd phase of the formalin test, suggesting that
opioid peptides are released. If we can replicate this finding with our antisera then we
can conclude specificity and sufficient diffusion of the antibodies to the target tissues in
the spinal cord.

2. In addition to the biochemical and intracellular mechanisms maintaining
constitutive activity, it may be of clinical relevance to elucidate the initiating mechanisms.
Shoblock et al. (2007) demonstrated the endogenous encephalin release is necessary
for morphine-mediated MORCA, suggesting that opioid peptides may be involved in the
first steps toward ligand-independent signaling. While it is difficult to speculate on how
enkephalins would promote the development of MORCA, their involvement can be tested.
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For example, a future study testing the hypothesis that endogenously released spinal
enkephalins drive the creation of MORCA can be tested by implanting an intrathecal
osmotic minipump, continuously secreting the neutral antagonist 6β-naltrexol, for the first
21d after a CFA injury. If the interaction of the peptide and receptor can be blocked with
the antagonist, then the intracellular signaling mechanisms that lower the allosteric
constant may not be triggered. On day 21 post injury and drug infusion, MORCA can be
assessed measuring GTPγS35 knockdown by β-funaltrexamine. The prediction is that
the antagonist and subsequent block of opioid peptide signaling would prevent the
development of MORCA. While this procedure is expected to increase hyperalgesia
through the drug infusion, just as NTX mini-pump infusion extended the duration of
mechanical hyperalgesia, it is a useful study to understand the initiating mechanism of
MORCA. The potential pitfalls of this study however may preclude any useful information:
on their own, chronic opioid receptor antagonists increase MOR expression in the spinal
cord. Constitutive activity is generated in in vitro cell-based assays by overexpressing
the receptor. Thus, we predict that chronic 6β-naltrexol infusion may increase spinal
MOR expression and produce constitutive activity via an alternate mechanism similar to
what occurs in these cellular systems. To circumvent this issue, preproenkephalin
knockout mice (penk1 null) could be generated and tested for the presence of MORCA
after injury.

Copyright © Gregory F. Corder 2013
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CHAPTER 5

Final Discussion

5.1. General Discussion
The main aims of this thesis were to investigate novel mechanisms that contribute to
or facilitate the transition from acute to chronic pain. Working from the experimental
framework of drug addiction theory and allostasis, we have designed and implemented
studies that implicate a dual role of the endogenous spinal µ-opioid receptor system to
chronic pain. In our model, the endogenous μ-opioid receptor system produces both a
long-lasting analgesia and a paradoxical sensitization of nociceptive pathways.
Opioid drugs, such as morphine, remain the gold-standard for clinical pain relief but
are severely limited by tolerance, dependence and addiction. However, the utility of the
intrinsic opioid system has been overlooked in the scientific literature. In this
dissertation, we demonstrate, for the first time, that injury produces a unique signaling
state for the µ-opioid receptor (MORCA). This signaling conformation allows for tonic
inhibitory signal transduction, independent of endogenous ligand stimulation. Inverse
agonists for the µ-opioid receptor precipitate somatic and aversive withdrawal
symptoms, indicative of endogenous physical and psychological dependence on µconstitutive activity. We further show that allostatic counter-adaptions occur, including
functional sensitization of NMDA-receptor and AC1 signaling pathways, which facilitate
escalating endogenous opioid dependence. To support these conclusions we used
controlled and blinded behavioral pharmacology, genetic knockout mice, molecular and
biochemical assays, and ex vivo spinal cord slice Ca2+ imagining studies.
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In conclusion, we have discovered a novel mechanism of long-lasting opioid
analgesia that regulates the transition from acute to chronic pain while, in parallel,
generates opioid dependence. Thus, the prevalence of chronic pain syndromes may
result from a failure in constitutive signaling of spinal MOR.
5.1.1 Allostatic mechanism for the emergence of chronic pain.
5.1.1.1. Persistent activity of inhibitory and excitatory opponent processes.
A single tissue injection of complete Freund’s adjuvant (CFA) to mice caused a
transient acute nociceptive hypersensitivity that resolved within several days. From this
timecourse we inferred that spontaneous pain recovery resulted from either deactivation
of pronociceptive systems or increased counter-adaptive endogenous inhibition. Using
behavioral pharmacology we blocked the endogenous spinal opioidergic system to
rekindle hyperalgesia, a phenomena we have termed “pain reinstatement.” We found
that pain reinstatement could be induced as early as 21 days after the injury when
inflammation was still present (Figure 2.1c), and as late as 200 days (Figure 2.2e) after
the injury when no signs of the physical injury were remained (discussed thoroughly in
Chapter 2, section 2.4.1.).
A long history of scientific literature has demonstrated that strong noxious input
into the spinal cord is accompanied by the release of opioid peptides, increased opioid
receptor density and enhanced opioid receptor─G-protein coupling within the dorsal
horn (Yaksh and Elde, 1981; Basbaum and Fields, 1984; Iadarola et al., 1986; Noguchi
et al., 1992; Mousa et al., 2002; Song and Marvizon, 2003; Schepers et al., 2008b;
Mousa et al., 2002; Calza et al., 2000; Goff et al., 1998; Shaqura et al., 2004). Here we
have presented similar evidence that the opioidergic systems are activated or “turned
on” after CFA to promote the resolution of acute hypersensitivity (i.e. naltrexone (NTX)
osmotic pump prevents pain recovery). Furthermore, at the 21d timepoint, we found
139

significant increases in the functional capacity for spinal µ-opioid receptors (MORs) to
couple G-proteins (i.e. increased DAMGO-stimulated GTPγS35 binding) by a ligandindependent mechanism. Which when disrupted by intrathecal pertussis toxin, naloxone,
NTX, CTOP or β-funaltrexamine (β-FNA) induced pain reinstatement. Therefore, from
this data one possible conclusion is that spinal MORs provide substantial endogenous
analgesia by tonically suppressing on-going nociception, central sensitization or a spinal
“pain engram”. While this is the simplest, most straightforward interpretation of these
results (discussed thoroughly in Chapter 2), we have discovered divergent evidence to
suggest that long-lived MORCA becomes pathological in promoting this persistent
sensitization of the nociceptive pathway (i.e. endogenous opioid dependence).
During the initial recovery of acute CFA-induced hyperalgesia opioid peptides are
released in the spinal cord to activate opioid receptors. I believe that the stimulation of
opioid receptors by endogenous ligands during this recovery period promotes the
acquisition of MORCA, which appears to last for months after the injury. This chronic
endogenous signaling in turn drives the upregulation of AC1, making the system
dependent on MORCA to continue to inhibit the now potentiated AC1 system.

An

analogous mechanism occurs with long-term exposure of opiate drugs: Chronic
administration of exogenous opiates leads to the development of compensatory
neuroadaptations underlying opiate tolerance and dependence (Christie, 2008),
including the selective upregulation of calcium-sensitive AC isoforms (Avidor-Reiss et
al., 1997; Lane-Ladd et al., 1997). Likewise, these same opiate dosing paradigms can
induce MORCA, which is enhanced by the presence of endogenously released
enkephalin peptides (Shoblock and Maidment, 2007). Therefore, this dissertation
proposes that opioidergic signaling loses its physiological utility in countering nociception
when the receptor cannot “turn off” and enters a vicious cycle of ever increasing counteradaptive processes, described here further as an allostatic load.
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5.1.1.2. Principles of allostasis relating to chronic pain.
Pain has been described as a homeostatic emotion, involving sensory and
cognitive control of nociceptive information that travels through the spinal cord, reflecting
an adverse condition that requires a behavioral response to maintain stability (Craig,
2003).

Homeostasis is a core principle of physiology that corresponds to the

mechanisms that maintain stability within a system: deviation from a specific set-point is
corrected by negative feedback loops that regulate physiologic parameters in order to
ensure survival of the organism. Based on this viewpoint one assumes that as physical
injuries heal, pain resolves in parallel, and both pro-nociceptive and anti-nociceptive
processes return to their pre-injury levels in a homeostatic manner. However, chronic
pain syndromes may spontaneously re-occur months or years after an injury
(Andersson, 1999). The mechanisms that drive the reemergence of chronic pain are not
well understood, but clearly argue that some facet of the nociceptive system has
undergone stable adaptations that facilitate the expression of persistent pain states and
do not comply with the principles of homeostasis.
In contrast, the principles of allostasis state that the processes of maintaining
stability are achieved through change of integrative systems that create a new balanced
set-point (McEwen, 2003). Thus, an allostatic state can be defined as a state of chronic
deviation of the regulatory systems from their normal state of operation with the
establishment of this new set-point (McEwen, 2003). The persistence of an allostatic
state is hypothesized to undergo a collapse or breakdown. This occurs when the
opposing systems reach a maximum and become stressed such that new set-points
cannot be maintained (e.g. loss of stability). This chronic state is referred to as an
allostatic load, defined as “the cost or the price the body may have to pay for being
forced to adapt to an adverse or deleterious psychological or physical situation, and it
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represents the presence of too much demand on the operation of the regulatory systems
- mainly the primary mediators of the physiological response — or their failure to relax
when the demand is over.” (Koob and Le Moal, 2001). The allostatic load hypothesis has
been proposed to underlie several disease states, including drug addiction (Koob and Le
Moal, 2001), migraine (Borsook et al., 2012), and latent pain sensitization (Celerier et al.,
2001).
5.1.1.3. Overarching allostatic theory of chronic pain
Thus, while the physical tissue may heal, we propose that the neural composition
of the nociceptive system does not homeostatically return to a pre-injury state. Rather, a
new, elevated balance (set point) between inhibitory (opioidergic) and excitatory (NMDARs and AC1) systems is created (i.e. endogenous opioid physical dependence), thereby
“priming” the system for recurring pain should the inhibitory system fail. Therefore, we
propose that the emergence of chronic pain is the result of a breakdown in the allostatic
load between MORCA and the opposing systems that maintain endogenous opioid
dependence (Figure 5.1).
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Figure 5.1. Breakdown of the allostatic load between MORCA and pronociceptive
mechanisms establishes chronic pain.
The allostatic state (i.e. physical dependence) persists for months after the injury has
recovered. The degree of opioid physical dependence continues to intensify and we
hypothesize that over time the high demands on MORCA will cause a breakdown in the
allostatic load (a natural withdrawal state). This natural withdrawal could theoretically
occur during menopause when estrogen levels drop or during states of chronic stress or
depression. At the cellular level this breakdown may induce de novo LTP that further
strengthens synaptic facilitation and promotes the full emergence of chronic pain (Figure
5.2).
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5.1.2. MORCA dysfunction: a mechanism of chronic pain?
It is inviting to speculate that the transition to chronic pain involves dysfunction of
endogenous MOR signaling, possibly via mechanisms involving cellular tolerance,
anxiety or stress. While we did not detect the presence of analgesic tolerance here,
studies have shown non-nociceptive stress can precipitate hyperalgesia after injury
recovery (Le Roy et al., 2011), which may rely on the anti-opioid effects of
cholecystokinin (Zhang et al., 2009). A few clinical chronic pain studies have suggested
that a transient up-regulation of endogenous opioid analgesia, followed by opioid
dysfunction is associated with the onset of chronic pain (Bruehl et al., 2004; Bruehl et al.,
2010). Future therapeutic strategies for chronic pain designed to strengthen endogenous
opioid signaling will have to consider the pitfalls of countering pro-nociceptive systems
while concomitantly creating an allostatic state.
5.1.2.1. Clinical evidence of MORCA: Endogenous opioidergic analgesia and
dependence
Opioid receptor antagonists, such as naloxone can produce hyperalgesia in
humans, indicating the presence of endogenous opioid analgesia Buchsbaum et al.,
1977; Jungkunz et al. 1983; Frid et al. 1981; Levine et al. 1979; Gracely et al., 1986;
Anderson et al., 2002). Furthermore, tonic pain causes the release of endogenous
substances acting at MORs in the brain (Zubieta et al., 2001), and induces long-lasting
activation of spinal MOR (Tambeli et al., 2009). Our data suggest that endogenous
activation of MORs will initiate both analgesic signaling as well as a standard
compensatory opponent-processes that can lead to a rebound effect when an inverse
agonist is given (i.e. withdrawal symptoms). Anecdotal evidence supports the idea that
endogenous opioidergic mechanisms lead to physical dependence in humans. For
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example, naltrexone can induce withdrawal-like symptoms including nausea and
jitteriness (Kaur et al., 2006).
5.1.2.2. Therapeutic strategies to target the MORCA and AC1 allostatic load
If the persistent allostatic load between MORCA and AC1 signaling pathways is
indeed responsible for priming individuals to develop chronic pain then clinically
efficacious and novel treatments (pre-emptive) may stem from preventing the formation
of the load or eliminating the load. Specifically, targeting the upregulation and/or
signaling components of spinal AC1 may prove most beneficial. Treatments should be
targeted to knockdown (RNAi or other gene silencing technologies) or pharmacologically
inhibit AC1 in order to erase the persistent sensitization, while retaining the benefits of
endogenous constitutive opioid signaling.

5.2. Conclusions
5.2.1. MORCA silences persistent AC1 central sensitization
We have identified an injury-induced MORCA that promotes both endogenous
analgesia and dependence. Our data suggest that long-term MORCA inhibition of AC1mediated central sensitization drives a counter-adaptive, homeostatic increase in
pronociceptive

AC1

signaling

cascade,

thereby

paradoxically

promoting

the

maintenance of latent central sensitization. Thus, injury produces a long-lasting
dependence on MORCA that tonically prevents withdrawal hyperalgesia, consistent with
proposed mechanisms of dependence to opiate drugs such as morphine (Zahariou et
al., 2008; Li et al. 2006). These data indicate that blockade of MORCA unmasks a silent
AC1 central sensitization pathway that persists beyond the resolution of pain and
inflammation, reflective of hyperalgesic priming (Asiedu et al. 2011).
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The presence of contralateral spinal MORCA and neural sensitization illustrates
the spread of this pathology to areas of the CNS beyond those directly innervated by the
injured tissue. Thus MORCA might tonically repress wide-spread hyperalgesia. Unilateral
injuries often produce bilateral hyperalgesia, and the current data extends this to latent
pain sensitization in CFA 21-day mice. NTX produced bilateral hyperalgesia and
bilaterally increased stimulus-evoked pERK expression. Leading explanations for
bilateral hyperalgesia include descending facilitatory fibers from the brainstem (Chai et
al. 2011; Tillu et al., 2008) and reactive spinal astrocytes communicating through gapjunction networks (Gao et al. 2010; Hatashita et al., 2008). We found evidence for
bilateral expression of MORCA, namely contralateral increases in DAMGO-induced MORG-protein coupling and β-funaltrexamine-induced decreases in basal MOR-G-protein
coupling. We suggest that MORCA is intricately involved in the regulation of contralateral
sensitization, and thus chronic pain phenotypes that display widespread hypersensitivity,
such as fibromyalgia. If true, then loss of MORCA antinociception (e.g. during stress)
could lead to the emergence of rampant chronic pain (De Felice et al., 2010; Rivat et al.,
2007).
5.2.2. MORCA promotes the existence of AC1 central sensitization to establish
cellular dependence
While MORCA provides lasting antinociception, our findings indicate that
prolonged MORCA promotes cellular consequences of dependence including potentiated
NMDA-R–derived Ca2+ mobilization and downstream activation of AC1 leading to cAMP
overshoot. Upregulated AC1 function facilitates morphine dependence (Li et al., 2006;
Zachariou et al., 2008) and chronic pain (Wei et al., 2002; Zhuo, 2012), in part by
promoting phosphorylation and trafficking of AMPA receptors via PKA (Lu et al., 2003;
Xu et al., 2008) or PKMζ (Li et al., 2010), and promoting phosphorylation of NMDA-Rs
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via PKA─Src kinase (Qiu et al., 2013) to increase synaptic strength during LTP. Spinal
LTP at C-fiber synapses occurs during opiate withdrawal (Drdla et al., 2009). Similar
synaptic mechanisms may underlie withdrawal from MORCA.
The overall conclusion from this body of work is that loss of MORCA, and the
ensuing reinstatement of pain, reflects a process of spinal cellular withdrawal and AC1
superactivation to enhance pronociceptive synaptic strength (Figure 5.2). This raises the
prospect that the opposing interactions between MORCA and latent NMDA-R–AC1
sensitization create a lasting susceptibility to develop chronic pain.
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Figure 5.2. Endogenous MORCA withdrawal facilitates the reinstatement of pain by
induction of de novo NMDA-R-dependent LTP in spinal nociceptive circuits.
Left: MORs in the spinal nociceptive system acquire constitutive activity (MORCA) after
injury which chronically inhibit AC1. Due to this chronic inhibition of the AC-cAMP-PKA
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pathway there is a compensatory increase in AC1 and possibly PKA expression. This
increase in spinal AC1 maintains a state of endogenous MORCA dependence.
Right: When MORCA is disrupted by the inverse agonists, such as NTX, CTOP or β-FNA,
the upregulated AC1 population becomes superactivated by NMDA-R/VGCC-derived
calcium, producing a cAMP overshoot response. Elevated levels of cAMP act upon the
potentiated PKA population which would drive several mechanisms to induce LTP:
increased glutamate neurotransmitter release from presynaptic boutons, augmented
gene expression, phosphorylation and synaptic insertion of postsynaptic AMPA-Rs and
phosphorylation of NDMA-Rs.
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APPENDIX

Appendix 1. Abbreviations
5-HT

Serotonin

7TM-R

Seven transmembrane receptor

AC

Adenylyl cyclase

AC1

Adenylyl cyclase type 1

AMPA

alpha-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid

ANOVA

Analysis of variance

AUC

Area under Curve

β-FNA

Beta-funaltrexamine

CaMKII

Ca2+/calmodulin-dependent kinase II

cAMP

adenosine 3′,5′-cyclic monophosphate

CB1

Cannabinoid receptor 1

CCK

Cholecystokinin

CFA

Complete Freund’s adjuvant

CNS

Central nervous system

CONTRA

Contralateral

CPP

Conditioned place preference

CPxSx

Common peroneal nerve transection, sural nerve transection

CREB

cAMP response element binding protein

CTOP

Phe-Cys-Tyr-Trp-Orn-Thr-Pen-Thr-NH2

DAMGO

[D-Ala2, N-Me-Phe4, Gly5-ol]-Enkephalin

DMSO

Dimethyl sulfoxide
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EC50

Half maximal effective concentration

ELISA

Enzyme-Linked Immunosorbent Assay

EMAX

Maximum possible effect

ERK

Extracellular-signal-regulated kinases

Fura-2 AM

Acetoxymethyl 2-[5-[bis[(acetoxymethoxyoxoymethyl)methyl]amino]-4-[2-[2-[bis[(acetoxymethoxy-oxomethyl)methyl]amino]-5-methyl-phenoxy]ethoxy]benzofuran2-yl]oxazole-5-carboxylate

GABA

Gamma-aminobutyric acid

CGRP

Calcitonin gene-related peptide

GDP

Guanosine diphosphate

GIRK

G-protein linked inward rectifying potassium channel

GPCR

G-protein coupled receptor

GTP

Guanosine triphosphate

GTPγS35

Guanosine-5’-O-(3-[35S]thio)triphosphate

HFS

High frequency stimulation

IASP

International Association for the Study of Pain

IPSI

Ipsilateral

LC

Locus coeruleus

LTP

Long-term potentiation

MAPK

Mitogen-activated protein kinase

MK-801

(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d] cyclohepten-5,10imine maleate)

MOR

Mu opioid receptor

MORCA

Mu opioid receptor constitutive activity

MPE

Maximum Possible Effect
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NeuN

Neuronal nuclei

NK1

Neurokinin receptor 1

NMB

Naltrexone methobromide

NMDA

N-methyl-D-aspartate

NPY

Neuropeptide tyrosine

NTX

Naltrexone

PAG

Periaquaductual gray

PB

Phosphate buffer

PBN

Parabrachial nucleus

PBS

Phosphate buffered saline

pERK

Phosphorylated extracellular-signal-regulated kinases

PKA

Protein kinase A

PKC

Protein kinase C

PKCζ

Atypical protein kinase zeta

RVM

Rostral ventral medulla

SNI

Spared nerve injury

SP

Substance P

TRPV1

Transient receptor potential vanilloid receptor-1

VGCC

Voltage gated calcium channel

WDR

Wide dynamic range neuron

Y1R

Neuropeptide tyrosine receptor 1
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